{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 75612, "items": [{"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T23:58:33Z", "timestamp": 1574812713948}, "publisher-location": "Cham", "reference-count": 40, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319300443", "type": "print"}, {"value": "9783319300467", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-30046-7_9", "type": "book-chapter", "created": {"date-parts": [[2016, 6, 29]], "date-time": "2016-06-29T08:38:22Z", "timestamp": 1467189502000}, "page": "139-151", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Urachal and Non-urachal Adenocarcinomas of the Bladder"], "prefix": "10.1007", "author": [{"given": "Arlene O.", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 6, 29]]}, "reference": [{"key": "9_CR1", "doi-asserted-by": "crossref", "first-page": "2165", "DOI": "10.1002/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-M", "volume": "67", "author": "DJ Grignon", "year": "1991", "unstructured": "Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991;67:2165\u201372.", "journal-title": "Cancer"}, {"key": "9_CR2", "doi-asserted-by": "crossref", "first-page": "376", "DOI": "10.1016/j.urology.2009.10.018", "volume": "75", "author": "G Lughezzani", "year": "2010", "unstructured": "Lughezzani G, Sun M, Jeldres C, et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology. 2010;75:376\u201381.", "journal-title": "Urology"}, {"key": "9_CR3", "doi-asserted-by": "crossref", "first-page": "623", "DOI": "10.1046/j.1464-410x.2001.02136.x", "volume": "87", "author": "N Smeulders", "year": "2001", "unstructured": "Smeulders N, Woodhouse CR. Neoplasia in adult exstrophy patients. BJU Int. 2001;87:623\u20138.", "journal-title": "BJU Int"}, {"key": "9_CR4", "doi-asserted-by": "crossref", "first-page": "50", "DOI": "10.1016/S0022-5347(17)63716-9", "volume": "93", "author": "TD Allen", "year": "1965", "unstructured": "Allen TD, Henderson BW. Adenocarcinoma of the bladder. J Urol. 1965;93:50\u20136.", "journal-title": "J Urol"}, {"key": "9_CR5", "doi-asserted-by": "crossref", "first-page": "705", "DOI": "10.1016/S0022-5347(17)67849-2", "volume": "71", "author": "FK Mostofi", "year": "1954", "unstructured": "Mostofi FK. Potentialities of bladder epithelium. J Urol. 1954;71:705\u201314.", "journal-title": "J Urol"}, {"key": "9_CR6", "doi-asserted-by": "crossref", "first-page": "380", "DOI": "10.1046/j.1365-2559.2000.0855e.x", "volume": "36", "author": "KT Mai", "year": "2000", "unstructured": "Mai KT, Yazdi HM, Perkins DG, et al. Multicentric clear cell adenocarcinoma in the urinary bladder and the urethral diverticulum: evidence of origin of clear cell adenocarcinoma of the female lower urinary tract from Mullerian duct remnants. Histopathology. 2000;36:380\u20132.", "journal-title": "Histopathology"}, {"key": "9_CR7", "doi-asserted-by": "crossref", "first-page": "13", "DOI": "10.1016/j.urolonc.2005.05.027", "volume": "24", "author": "MS Zaghloul", "year": "2006", "unstructured": "Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol. 2006;24:13\u201320.", "journal-title": "Urol Oncol"}, {"key": "9_CR8", "doi-asserted-by": "crossref", "first-page": "1656", "DOI": "10.1016/j.juro.2012.11.084", "volume": "189", "author": "F Dayyani", "year": "2013", "unstructured": "Dayyani F, Czerniak BA, Sircar K, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189:1656\u201361.", "journal-title": "J Urol"}, {"key": "9_CR9", "doi-asserted-by": "crossref", "first-page": "752", "DOI": "10.1097/PAS.0b013e318159af9e", "volume": "32", "author": "JY Ro", "year": "2008", "unstructured": "Ro JY, Shen SS, Lee HI, et al. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases. Am J Surg Pathol. 2008;32:752\u20137.", "journal-title": "Am J Surg Pathol"}, {"key": "9_CR10", "first-page": "381", "volume": "442", "author": "A Lopez-Beltran", "year": "2003", "unstructured": "Lopez-Beltran A, Luque RJ, Quintero A, et al. Hepatoid adenocarcinoma of the urinary bladder. Virchows Arch. 2003;442:381\u20137.", "journal-title": "Virchows Arch"}, {"key": "9_CR11", "doi-asserted-by": "crossref", "first-page": "1380", "DOI": "10.1097/00000478-200111000-00005", "volume": "25", "author": "HL Wang", "year": "2001", "unstructured": "Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001;25:1380\u20137.", "journal-title": "Am J Surg Pathol"}, {"key": "9_CR12", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.1046/j.1365-2559.1998.00328.x", "volume": "32", "author": "R Torenbeek", "year": "1998", "unstructured": "Torenbeek R, Lagendijk JH, Van Diest PJ, et al. Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. Histopathology. 1998;32:20\u20137.", "journal-title": "Histopathology"}, {"key": "9_CR13", "doi-asserted-by": "crossref", "first-page": "303", "DOI": "10.1097/00000478-200303000-00003", "volume": "27", "author": "RW Werling", "year": "2003", "unstructured": "Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303\u201310.", "journal-title": "Am J Surg Pathol"}, {"key": "9_CR14", "doi-asserted-by": "crossref", "first-page": "108", "DOI": "10.1016/j.humpath.2008.06.022", "volume": "40", "author": "AA Thomas", "year": "2009", "unstructured": "Thomas AA, Stephenson AJ, Campbell SC, et al. Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. Hum Pathol. 2009;40:108\u201316.", "journal-title": "Hum Pathol"}, {"key": "9_CR15", "doi-asserted-by": "crossref", "first-page": "206", "DOI": "10.1046/j.1464-410X.1998.00718.x", "volume": "82", "author": "MM El-Mekresh", "year": "1998", "unstructured": "El-Mekresh MM, El-Baz MA, Abol-Enein H, et al. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol. 1998;82:206\u201312.", "journal-title": "Br J Urol"}, {"key": "9_CR16", "first-page": "193", "volume": "15", "author": "MS Zaghloul", "year": "2003", "unstructured": "Zaghloul MS, Abdel Aziz S. Primary adenocarcinoma of the urinary bladder: risk factors and value of postoperative radiotherapy. J Egypt Natl Canc Inst. 2003;15:193\u2013200.", "journal-title": "J Egypt Natl Canc Inst"}, {"key": "9_CR17", "doi-asserted-by": "crossref", "first-page": "1295", "DOI": "10.1097/01.ju.0000054646.49381.01", "volume": "169", "author": "AO Siefker-Radtke", "year": "2003", "unstructured": "Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003;169:1295\u20138.", "journal-title": "J Urol"}, {"key": "9_CR18", "doi-asserted-by": "crossref", "first-page": "255", "DOI": "10.1016/j.urology.2006.10.029", "volume": "69", "author": "MD Galsky", "year": "2007", "unstructured": "Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69:255\u20139.", "journal-title": "Urology"}, {"key": "9_CR19", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/S0022-5347(17)50167-6", "volume": "131", "author": "CA Sheldon", "year": "1984", "unstructured": "Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol. 1984;131:1\u20138.", "journal-title": "J Urol"}, {"key": "9_CR20", "doi-asserted-by": "crossref", "first-page": "721", "DOI": "10.1002/cncr.22059", "volume": "107", "author": "JL Wright", "year": "2006", "unstructured": "Wright JL, Porter MP, Li CI, et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer. 2006;107:721\u20138.", "journal-title": "Cancer"}, {"key": "9_CR21", "doi-asserted-by": "crossref", "first-page": "635", "DOI": "10.1016/0090-4295(93)90526-G", "volume": "42", "author": "DR Henly", "year": "1993", "unstructured": "Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology. 1993;42:635\u20139.", "journal-title": "Urology"}, {"key": "9_CR22", "doi-asserted-by": "crossref", "first-page": "455", "DOI": "10.1016/j.urology.2013.09.034", "volume": "83", "author": "S Gupta", "year": "2014", "unstructured": "Gupta S, Bhaijee F, Harmon EP. Mucinous neoplasm arising in a urachal cyst: a first in the pediatric population. Urology. 2014;83:455\u20136.", "journal-title": "Urology"}, {"key": "9_CR23", "doi-asserted-by": "crossref", "first-page": "327", "DOI": "10.1016/j.humpath.2013.09.008", "volume": "45", "author": "SJ Sirintrapun", "year": "2014", "unstructured": "Sirintrapun SJ, Ward M, Woo J, et al. High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol. 2014;45:327\u201330.", "journal-title": "Hum Pathol"}, {"key": "9_CR24", "doi-asserted-by": "crossref", "first-page": "40", "DOI": "10.1016/S0022-5347(17)53595-8", "volume": "127", "author": "GE Schubert", "year": "1982", "unstructured": "Schubert GE, Pavkovic MB, Bethke-Bedurftig BA. Tubular urachal remnants in adult bladders. J Urol. 1982;127:40\u20132.", "journal-title": "J Urol"}, {"key": "9_CR25", "doi-asserted-by": "crossref", "first-page": "218", "DOI": "10.1016/0090-4295(85)90112-8", "volume": "26", "author": "DE Johnson", "year": "1985", "unstructured": "Johnson DE, Hodge GB, Abdul-Karim FW, et al. Urachal carcinoma. Urology. 1985;26:218\u201321.", "journal-title": "Urology"}, {"key": "9_CR26", "doi-asserted-by": "crossref", "first-page": "619", "DOI": "10.1053/j.seminoncol.2012.08.011", "volume": "39", "author": "A Siefker-Radtke", "year": "2012", "unstructured": "Siefker-Radtke A. Urachal adenocarcinoma: a clinician\u2019s guide for treatment. Semin Oncol. 2012;39:619\u201324.", "journal-title": "Semin Oncol"}, {"key": "9_CR27", "doi-asserted-by": "crossref", "first-page": "348", "DOI": "10.1080/02841850410004959", "volume": "45", "author": "M Takeuchi", "year": "2004", "unstructured": "Takeuchi M, Matsuzaki K, Yoshida S, et al. Imaging findings of Urachal mucinous cystadenocarcinoma associated with pseudomyxoma peritonei. Acta Radiol. 2004;45:348\u201350.", "journal-title": "Acta Radiol"}, {"key": "9_CR28", "doi-asserted-by": "crossref", "first-page": "712", "DOI": "10.1002/cncr.22060", "volume": "107", "author": "RA Ashley", "year": "2006", "unstructured": "Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107:712\u201320.", "journal-title": "Cancer"}, {"key": "9_CR29", "doi-asserted-by": "crossref", "first-page": "1102", "DOI": "10.1016/j.juro.2012.06.020", "volume": "188", "author": "HM Bruins", "year": "2012", "unstructured": "Bruins HM, Visser O, Ploeg M, et al. The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol. 2012;188:1102\u20137.", "journal-title": "J Urol"}, {"key": "9_CR30", "doi-asserted-by": "crossref", "first-page": "74", "DOI": "10.1016/j.juro.2007.03.022", "volume": "178", "author": "HW Herr", "year": "2007", "unstructured": "Herr HW, Bochner BH, Sharp D, et al. Urachal carcinoma: contemporary surgical outcomes. J Urol. 2007;178:74\u20138. discussion 78.", "journal-title": "J Urol"}, {"key": "9_CR31", "doi-asserted-by": "crossref", "first-page": "2434", "DOI": "10.1002/cncr.23070", "volume": "110", "author": "JR Molina", "year": "2007", "unstructured": "Molina JR, Quevedo JF, Furth AF, et al. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer. 2007;110:2434\u201340.", "journal-title": "Cancer"}, {"key": "9_CR32", "doi-asserted-by": "crossref", "first-page": "282", "DOI": "10.1159/000472031", "volume": "2", "author": "V Lane", "year": "1976", "unstructured": "Lane V. Prognosis in carcinoma of the urachus. Eur Urol. 1976;2:282\u20133.", "journal-title": "Eur Urol"}, {"key": "9_CR33", "doi-asserted-by": "crossref", "first-page": "360", "DOI": "10.1016/0090-4295(83)90152-8", "volume": "21", "author": "T Kakizoe", "year": "1983", "unstructured": "Kakizoe T. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology. 1983;21:360\u20136.", "journal-title": "Urology"}, {"key": "9_CR34", "doi-asserted-by": "crossref", "first-page": "252", "DOI": "10.1016/0090-4295(85)90121-9", "volume": "26", "author": "CJ Logothetis", "year": "1985", "unstructured": "Logothetis CJ, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. Urology. 1985;26:252\u20135.", "journal-title": "Urology"}, {"key": "9_CR35", "doi-asserted-by": "crossref", "first-page": "1361", "DOI": "10.1200/JCO.20.5.1361", "volume": "20", "author": "AO Siefker-Radtke", "year": "2002", "unstructured": "Siefker-Radtke AO, Millikan RE, Tu S-M, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2002;20:1361\u20137.", "journal-title": "J Clin Oncol: Off J Am Soc Clin Oncol"}, {"key": "9_CR36", "doi-asserted-by": "crossref", "first-page": "867", "DOI": "10.1016/j.juro.2008.05.017", "volume": "180", "author": "NM Tannir", "year": "2008", "unstructured": "Tannir NM, Thall PF, Ng CS, et al. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008;180:867\u201372. discussion 872.", "journal-title": "J Urol"}, {"key": "9_CR37", "doi-asserted-by": "crossref", "first-page": "1719", "DOI": "10.1016/S0022-5347(01)66765-X", "volume": "154", "author": "SM Tu", "year": "1995", "unstructured": "Tu SM, Hossan E, Amato R, et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol. 1995;154:1719\u201322.", "journal-title": "J Urol"}, {"key": "9_CR38", "doi-asserted-by": "crossref", "first-page": "402", "DOI": "10.1159/000362400", "volume": "59", "author": "Y Yanagihara", "year": "2013", "unstructured": "Yanagihara Y, Tanji N, Miura N, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013;59:402\u20136.", "journal-title": "Chemotherapy"}, {"key": "9_CR39", "doi-asserted-by": "crossref", "first-page": "1123", "DOI": "10.1111/j.1442-2042.2006.01487.x", "volume": "13", "author": "Y Kojima", "year": "2006", "unstructured": "Kojima Y, Yamada Y, Kamisawa H, et al. Complete response of a recurrent advanced urachal carcinoma treated by S-1/cisplatin combination chemotherapy. Int J Urol. 2006;13:1123\u20135.", "journal-title": "Int J Urol"}, {"key": "9_CR40", "doi-asserted-by": "crossref", "first-page": "281", "DOI": "10.1159/000091635", "volume": "76", "author": "H Kume", "year": "2006", "unstructured": "Kume H, Tomita K, Takahashi S, et al. Irinotecan as a new agent for urachal cancer. Urol Int. 2006;76:281\u20132.", "journal-title": "Urol Int"}], "container-title": ["Rare Genitourinary Tumors"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-30046-7_9", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 10]], "date-time": "2019-09-10T10:21:50Z", "timestamp": 1568110910000}, "score": 60.961037, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319300443", "9783319300467"], "references-count": 40, "URL": "http://dx.doi.org/10.1007/978-3-319-30046-7_9", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T18:23:19Z", "timestamp": 1576779799416}, "reference-count": 13, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "4", "license": [{"URL": "http://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 4, 1]], "date-time": "2003-04-01T00:00:00Z", "timestamp": 1049155200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Urology"], "published-print": {"date-parts": [[2003, 4]]}, "DOI": "10.1097/01.ju.0000054646.49381.01", "type": "journal-article", "created": {"date-parts": [[2004, 8, 25]], "date-time": "2004-08-25T21:11:48Z", "timestamp": 1093468308000}, "page": "1295-1298", "source": "Crossref", "is-referenced-by-count": 140, "title": ["Multimodality Management of Urachal Carcinoma: The M. D. Anderson Cancer Center Experience"], "prefix": "10.1097", "volume": "169", "author": [{"given": "ARLENE O.", "family": "SIEFKER-RADTKE", "sequence": "first", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}, {"given": "JASON", "family": "GEE", "sequence": "additional", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}, {"given": "Y.U.", "family": "SHEN", "sequence": "additional", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}, {"given": "SIJIN", "family": "WEN", "sequence": "additional", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}, {"given": "DANAI", "family": "DALIANI", "sequence": "additional", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}, {"given": "RANDALL E.", "family": "MILLIKAN", "sequence": "additional", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}, {"given": "LOUIS L.", "family": "PISTERS", "sequence": "additional", "affiliation": [{"name": "From the Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, Department of Urology and Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas"}]}], "member": "276", "container-title": ["Journal of Urology"], "language": "en", "link": [{"URL": "http://api.elsevier.com/content/article/PII:S0022534705637445?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://api.elsevier.com/content/article/PII:S0022534705637445?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 2]], "date-time": "2019-07-02T14:14:12Z", "timestamp": 1562076852000}, "score": 58.56238, "issued": {"date-parts": [[2003, 4]]}, "references-count": 13, "journal-issue": {"published-print": {"date-parts": [[2003, 4]]}, "issue": "4"}, "alternative-id": ["10.1097/01.ju.0000054646.49381.01"], "URL": "http://dx.doi.org/10.1097/01.ju.0000054646.49381.01", "ISSN": ["0022-5347", "1527-3792"], "issn-type": [{"value": "0022-5347", "type": "print"}, {"value": "1527-3792", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T18:23:19Z", "timestamp": 1576779799349}, "reference-count": 29, "publisher": "Informa UK Limited", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Review of Anticancer Therapy"], "published-print": {"date-parts": [[2006, 12]]}, "DOI": "10.1586/14737140.6.12.1715", "type": "journal-article", "created": {"date-parts": [[2006, 12, 21]], "date-time": "2006-12-21T11:53:23Z", "timestamp": 1166702003000}, "page": "1715-1721", "source": "Crossref", "is-referenced-by-count": 64, "title": ["Urachal carcinoma: surgical and chemotherapeutic options"], "prefix": "10.1586", "volume": "6", "author": [{"given": "Arlene", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 1, 10]]}, "reference": [{"key": "CIT0001", "author": "Sheldon", "volume": "131", "first-page": "1", "year": "1984", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)50167-6", "doi-asserted-by": "crossref"}, {"key": "CIT0002", "author": "Henly", "volume": "42", "first-page": "635", "year": "1993", "journal-title": "Urology", "DOI": "10.1016/0090-4295(93)90526-G", "doi-asserted-by": "crossref"}, {"key": "CIT0003", "author": "Siefker-Radtke", "volume": "169", "first-page": "1295", "year": "2003", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000054646.49381.01", "doi-asserted-by": "crossref"}, {"key": "CIT0004", "author": "Wright", "volume": "107", "first-page": "721", "year": "2006", "journal-title": "Cancer", "DOI": "10.1002/cncr.22059", "doi-asserted-by": "crossref"}, {"key": "CIT0005", "author": "Ashley", "volume": "107", "first-page": "712", "year": "2006", "journal-title": "Cancer", "DOI": "10.1002/cncr.22060", "doi-asserted-by": "crossref"}, {"key": "CIT0006", "author": "Schubert", "volume": "127", "first-page": "40", "year": "1982", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)53595-8", "doi-asserted-by": "crossref"}, {"key": "CIT0007", "author": "Begg", "volume": "64", "first-page": "170", "year": "1930", "journal-title": "J. Anat."}, {"key": "CIT0008", "author": "Hammond", "volume": "80", "first-page": "271", "year": "1941", "journal-title": "Anat. Rec.", "DOI": "10.1002/ar.1090800302", "doi-asserted-by": "crossref"}, {"key": "CIT0009", "author": "Johnson", "volume": "26", "first-page": "218", "year": "1985", "journal-title": "Urology", "DOI": "10.1016/0090-4295(85)90112-8", "doi-asserted-by": "crossref"}, {"key": "CIT0010", "author": "Grignon", "volume": "67", "first-page": "2165", "year": "1991", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19910415)67:8<2165::AID-CNCR2820670827>3.0.CO;2-M", "doi-asserted-by": "crossref"}, {"key": "CIT0011", "author": "Shaw", "volume": "79", "first-page": "815", "year": "1958", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)66349-3", "doi-asserted-by": "crossref"}, {"key": "CIT0012", "author": "Wheeler", "volume": "7", "first-page": "119", "year": "1954", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(195401)7:1<119::AID-CNCR2820070113>3.0.CO;2-8", "doi-asserted-by": "crossref"}, {"key": "CIT0013", "author": "Mostofi", "volume": "8", "first-page": "741", "year": "1955", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(1955)8:4<741::AID-CNCR2820080417>3.0.CO;2-C", "doi-asserted-by": "crossref"}, {"key": "CIT0014", "unstructured": "Siefker-Radtke AO, Czerniak BA, Dinney CP, Millikan RE. Uncommon cancers of the bladder. In:Textbook of Uncommon Cancer, Third Edition. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG (Eds). John Wiley & Sons, NJ, USA 18\u201326 (2006).", "DOI": "10.1002/0470030542.ch2", "doi-asserted-by": "crossref"}, {"key": "CIT0015", "author": "Takeuchi", "volume": "45", "first-page": "348", "year": "2004", "journal-title": "Acta Radiologica", "DOI": "10.1080/02841850410004959", "doi-asserted-by": "crossref"}, {"key": "CIT0016", "author": "Kikuno", "volume": "166", "first-page": "19", "year": "2001", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(05)65995-2", "doi-asserted-by": "crossref"}, {"key": "CIT0017", "author": "Guarnaccia", "volume": "145", "first-page": "140", "year": "1991", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)38271-X", "doi-asserted-by": "crossref"}, {"key": "CIT0018", "author": "Milhoua", "volume": "67", "first-page": "423.E15", "year": "2006", "journal-title": "Urology", "DOI": "10.1016/j.urology.2005.08.044", "doi-asserted-by": "crossref"}, {"key": "CIT0019", "author": "Wadhwa", "volume": "67", "first-page": "837", "year": "2006", "journal-title": "Urology", "DOI": "10.1016/j.urology.2005.10.048", "doi-asserted-by": "crossref"}, {"key": "CIT0020", "author": "Madeb", "volume": "98", "first-page": "838", "year": "2006", "journal-title": "Br. J. Urol. Int.", "DOI": "10.1111/j.1464-410X.2006.06430.x", "doi-asserted-by": "crossref"}, {"key": "CIT0021", "author": "Herr", "volume": "151", "first-page": "365", "year": "1994", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)34950-9", "doi-asserted-by": "crossref"}, {"key": "CIT0022", "author": "Pinthus", "volume": "175", "first-page": "2042", "year": "2006", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(06)00263-1", "doi-asserted-by": "crossref"}, {"key": "CIT0023", "author": "Lane", "volume": "2", "first-page": "282", "year": "1976", "journal-title": "Eur. Urol.", "DOI": "10.1159/000472031", "doi-asserted-by": "crossref"}, {"key": "CIT0024", "author": "Kakizoe", "volume": "21", "first-page": "360", "year": "1983", "journal-title": "Urology", "DOI": "10.1016/0090-4295(83)90152-8", "doi-asserted-by": "crossref"}, {"key": "CIT0025", "author": "Logothetis", "volume": "26", "first-page": "252", "year": "1985", "journal-title": "Urology", "DOI": "10.1016/0090-4295(85)90121-9", "doi-asserted-by": "crossref"}, {"key": "CIT0026", "author": "Siefker-Radtke", "volume": "20", "first-page": "1361", "year": "2002", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.20.5.1361", "doi-asserted-by": "crossref"}, {"key": "CIT0027", "author": "Kojima", "volume": "13", "first-page": "1123", "year": "2006", "journal-title": "Int. J. Urol.", "DOI": "10.1111/j.1442-2042.2006.01487.x", "doi-asserted-by": "crossref"}, {"key": "CIT0028", "author": "Kume", "volume": "76", "first-page": "281", "year": "2006", "journal-title": "Urol. Int.", "DOI": "10.1159/000091635", "doi-asserted-by": "crossref"}, {"key": "CIT0029", "author": "Galsky", "volume": "24", "first-page": "4542", "year": "2006", "journal-title": "J. Clin. Oncol."}], "container-title": ["Expert Review of Anticancer Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1586/14737140.6.12.1715", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 23]], "date-time": "2019-04-23T08:56:19Z", "timestamp": 1556009779000}, "score": 54.75582, "issued": {"date-parts": [[2006, 12]]}, "references-count": 29, "journal-issue": {"published-online": {"date-parts": [[2014, 1, 10]]}, "published-print": {"date-parts": [[2006, 12]]}, "issue": "12"}, "alternative-id": ["10.1586/14737140.6.12.1715"], "URL": "http://dx.doi.org/10.1586/14737140.6.12.1715", "relation": {"cites": []}, "ISSN": ["1473-7140", "1744-8328"], "issn-type": [{"value": "1473-7140", "type": "print"}, {"value": "1744-8328", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T18:23:24Z", "timestamp": 1576779804672}, "reference-count": 23, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 10, 1]], "date-time": "2012-10-01T00:00:00Z", "timestamp": 1349049600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Seminars in Oncology"], "published-print": {"date-parts": [[2012, 10]]}, "DOI": "10.1053/j.seminoncol.2012.08.011", "type": "journal-article", "created": {"date-parts": [[2012, 10, 2]], "date-time": "2012-10-02T20:15:21Z", "timestamp": 1349208921000}, "page": "619-624", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Urachal Adenocarcinoma: A Clinician's Guide for Treatment"], "prefix": "10.1053", "volume": "39", "author": [{"given": "Arlene", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Seminars in Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0093775412001601?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0093775412001601?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 4]], "date-time": "2019-07-04T10:57:03Z", "timestamp": 1562237823000}, "score": 51.369583, "issued": {"date-parts": [[2012, 10]]}, "references-count": 23, "journal-issue": {"published-print": {"date-parts": [[2012, 10]]}, "issue": "5"}, "alternative-id": ["S0093775412001601"], "URL": "http://dx.doi.org/10.1053/j.seminoncol.2012.08.011", "ISSN": ["0093-7754"], "issn-type": [{"value": "0093-7754", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T04:22:03Z", "timestamp": 1574396523828}, "reference-count": 11, "publisher": "Informa UK Limited", "issue": "12", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Review of Anticancer Therapy"], "published-print": {"date-parts": [[2009, 12]]}, "DOI": "10.1586/era.09.146", "type": "journal-article", "created": {"date-parts": [[2009, 12, 2]], "date-time": "2009-12-02T14:39:27Z", "timestamp": 1259764767000}, "page": "1701-1703", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure"], "prefix": "10.1586", "volume": "9", "author": [{"given": "Arlene O", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 1, 10]]}, "reference": [{"key": "CIT0001", "author": "Sternberg", "volume": "133", "first-page": "403", "year": "1985", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)48996-8", "doi-asserted-by": "crossref"}, {"key": "CIT0002", "author": "von der Maase", "volume": "18", "first-page": "3068", "year": "2000", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2000.18.17.3068", "doi-asserted-by": "crossref"}, {"key": "CIT0003", "author": "Bajorin", "volume": "17", "first-page": "3173", "year": "1999", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1999.17.10.3173", "doi-asserted-by": "crossref"}, {"key": "CIT0004", "author": "Dimopoulos", "volume": "151", "first-page": "598", "year": "1994", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)35025-5", "doi-asserted-by": "crossref"}, {"key": "CIT0005", "author": "Dodd", "volume": "17", "first-page": "2546", "year": "1999", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1999.17.8.2546", "doi-asserted-by": "crossref"}, {"key": "CIT0006", "author": "Millikan", "volume": "19", "first-page": "4005", "year": "2001", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2001.19.20.4005", "doi-asserted-by": "crossref"}, {"key": "CIT0007", "author": "Siefker-Radtke", "volume": "20", "first-page": "1361", "year": "2002", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.20.5.1361", "doi-asserted-by": "crossref"}, {"key": "CIT0008", "author": "Siefker-Radtke", "volume": "27", "first-page": "251s", "year": "2009", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2008.19.0256", "doi-asserted-by": "crossref"}, {"key": "CIT0009", "author": "Nieuwenhuijzen", "volume": "174", "first-page": "80", "year": "2005", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000162018.40891.ba", "doi-asserted-by": "crossref"}, {"key": "CIT0010", "author": "Sweeney", "volume": "169", "first-page": "2113", "year": "2003", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000067601.29966.4a", "doi-asserted-by": "crossref"}, {"key": "CIT0011", "author": "Siefker-Radtke", "volume": "171", "first-page": "145", "year": "2004", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000099823.60465.e6", "doi-asserted-by": "crossref"}], "container-title": ["Expert Review of Anticancer Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1586/era.09.146", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 24]], "date-time": "2019-05-24T05:28:15Z", "timestamp": 1558675695000}, "score": 49.60174, "issued": {"date-parts": [[2009, 12]]}, "references-count": 11, "journal-issue": {"published-online": {"date-parts": [[2014, 1, 10]]}, "published-print": {"date-parts": [[2009, 12]]}, "issue": "12"}, "alternative-id": ["10.1586/era.09.146"], "URL": "http://dx.doi.org/10.1586/era.09.146", "relation": {"cites": []}, "ISSN": ["1473-7140", "1744-8328"], "issn-type": [{"value": "1473-7140", "type": "print"}, {"value": "1744-8328", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T13:02:44Z", "timestamp": 1574427764738}, "reference-count": 41, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2010, 5, 6]], "date-time": "2010-05-06T00:00:00Z", "timestamp": 1273104000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Curr Oncol Rep"], "published-print": {"date-parts": [[2010, 7]]}, "DOI": "10.1007/s11912-010-0104-5", "type": "journal-article", "created": {"date-parts": [[2010, 5, 5]], "date-time": "2010-05-05T03:21:33Z", "timestamp": 1273029693000}, "page": "278-283", "source": "Crossref", "is-referenced-by-count": 5, "title": ["Bladder Cancer: Can We Move Beyond Chemotherapy?"], "prefix": "10.1007", "volume": "12", "author": [{"given": "Arlene", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2010, 5, 6]]}, "reference": [{"key": "104_CR1", "doi-asserted-by": "crossref", "first-page": "403", "DOI": "10.1016/S0022-5347(17)48996-8", "volume": "133", "author": "CN Sternberg", "year": "1985", "unstructured": "Sternberg CN, Yagoda A, Scher HI, et al.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403\u2013407.", "journal-title": "J Urol"}, {"key": "104_CR2", "doi-asserted-by": "crossref", "first-page": "3068", "DOI": "10.1200/JCO.2000.18.17.3068", "volume": "18", "author": "H Maase von der", "year": "2000", "unstructured": "von der Maase H, Hansen SW, Roberts JT, et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068\u20133077.", "journal-title": "J Clin Oncol"}, {"key": "104_CR3", "doi-asserted-by": "crossref", "first-page": "859", "DOI": "10.1056/NEJMoa022148", "volume": "349", "author": "HB Grossman", "year": "2003", "unstructured": "Grossman HB, Natale RB, Tangen CM, et al.: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [erratum appears in N Engl J Med 2003, 349:1880]. N Engl J Med 2003, 349:859\u2013866.", "journal-title": "N Engl J Med"}, {"key": "104_CR4", "doi-asserted-by": "crossref", "first-page": "1050", "DOI": "10.1200/JCO.1990.8.6.1050", "volume": "8", "author": "CJ Logothetis", "year": "1990", "unstructured": "Logothetis CJ, Dexeus FH, Finn L, et al.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990, 8:1050\u20131055.", "journal-title": "J Clin Oncol"}, {"key": "104_CR5", "doi-asserted-by": "crossref", "first-page": "2272", "DOI": "10.1200/JCO.1995.13.9.2272", "volume": "13", "author": "CJ Logothetis", "year": "1995", "unstructured": "Logothetis CJ, Finn LD, Smith T, et al.: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995, 13:2272\u20132277.", "journal-title": "J Clin Oncol"}, {"key": "104_CR6", "doi-asserted-by": "crossref", "first-page": "408", "DOI": "10.1200/JCO.1993.11.3.408", "volume": "11", "author": "AD Seidman", "year": "1993", "unstructured": "Seidman AD, Scher HI, Gabrilove JL, et al.: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993, 11:408\u2013414.", "journal-title": "J Clin Oncol"}, {"key": "104_CR7", "doi-asserted-by": "crossref", "first-page": "483", "DOI": "10.1200/JCO.1994.12.3.483", "volume": "12", "author": "PJ Loehrer Sr", "year": "1994", "unstructured": "Loehrer PJ Sr, Elson P, Dreicer R, et al.: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994, 12:483\u2013488.", "journal-title": "J Clin Oncol"}, {"key": "104_CR8", "doi-asserted-by": "crossref", "first-page": "220", "DOI": "10.1200/JCO.2004.02.152", "volume": "22", "author": "A Bamias", "year": "2004", "unstructured": "Bamias A, Aravantinos G, Deliveliotis C, et al.: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004, 22:220\u2013228.", "journal-title": "J Clin Oncol"}, {"key": "104_CR9", "doi-asserted-by": "crossref", "first-page": "1361", "DOI": "10.1200/JCO.2002.20.5.1361", "volume": "20", "author": "AO Siefker-Radtke", "year": "2002", "unstructured": "Siefker-Radtke AO, Millikan RE, Tu SM, et al.: Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002, 20:1361\u20131367.", "journal-title": "J Clin Oncol"}, {"key": "104_CR10", "doi-asserted-by": "crossref", "first-page": "2638", "DOI": "10.1200/JCO.2001.19.10.2638", "volume": "19", "author": "CN Sternberg", "year": "2001", "unstructured": "Sternberg CN, de Mulder PH, Schornagel JH, et al.: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001, 19:2638\u20132646.", "journal-title": "J Clin Oncol"}, {"key": "104_CR11", "first-page": "269s", "volume": "26", "author": "A Siefker-Radtke", "year": "2008", "unstructured": "Siefker-Radtke A, Millikan, RE, Kamat, AM, et al.: A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine, and ifosfamide (CGI) in locally advanced urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 2008, 26:269s.", "journal-title": "D. Anderson Cancer Center. J Clin Oncol"}, {"key": "104_CR12", "doi-asserted-by": "crossref", "first-page": "1671", "DOI": "10.1002/(SICI)1097-0142(20000401)88:7<1671::AID-CNCR22>3.0.CO;2-A", "volume": "88", "author": "DF Bajorin", "year": "2000", "unstructured": "Bajorin DF, McCaffrey JA, Dodd PM, et al.: Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000, 88:1671\u20131678.", "journal-title": "Cancer"}, {"key": "104_CR13", "unstructured": "\u2022\u2022 Siefker-Radtke A, Kamat A, Williams D, et al.: A phase II randomized four-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 2009, 27:251s. This clinical trial used a novel statistical design in sequential therapy that incorporates response to continue treatment that is working, with early re-randomization in the setting of suboptimal response."}, {"key": "104_CR14", "unstructured": "\u2022 Milowsky MI, Nanus DM, Maluf FC, et al.: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol 2009, 27:4062\u20134067. This is a sequential clinical trial design using a fixed schedule of chemotherapy.", "DOI": "10.1200/JCO.2008.21.2241", "doi-asserted-by": "crossref"}, {"key": "104_CR15", "doi-asserted-by": "crossref", "first-page": "1011", "DOI": "10.1002/(SICI)1097-0258(20000430)19:8<1011::AID-SIM414>3.0.CO;2-M", "volume": "19", "author": "PF Thall", "year": "2000", "unstructured": "Thall PF, Millikan RE, Sung HG: Evaluating multiple treatment courses in clinical trials. Stat Med 2000, 19:1011\u20131028.", "journal-title": "Stat Med"}, {"key": "104_CR16", "unstructured": "\u2022 Siefker-Radtke AO, Kamat AM, Grossman HB, et al.: Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009, 27:2592\u20132597. This is the first clinical trial in small cell urothelial cancer. Though it is a small clinical trial, it suggests a potential impact for neoadjuvant chemotherapy in small cell of the bladder.", "DOI": "10.1200/JCO.2008.19.0256", "doi-asserted-by": "crossref"}, {"key": "104_CR17", "doi-asserted-by": "crossref", "first-page": "1295", "DOI": "10.1097/01.ju.0000054646.49381.01", "volume": "169", "author": "AO Siefker-Radtke", "year": "2003", "unstructured": "Siefker-Radtke AO, Gee J, Shen Y, et al.: Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol 2003, 169:1295\u20131298.", "journal-title": "J Urol"}, {"key": "104_CR18", "doi-asserted-by": "crossref", "first-page": "907", "DOI": "10.1016/j.juro.2009.05.024", "volume": "182", "author": "SF Shariat", "year": "2009", "unstructured": "Shariat SF, Lotan Y, Karakiewicz PI, et al.: p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol 2009, 182:907\u2013913.", "journal-title": "J Urol"}, {"key": "104_CR19", "doi-asserted-by": "crossref", "first-page": "4005", "DOI": "10.1200/JCO.2001.19.20.4005", "volume": "19", "author": "R Millikan", "year": "2001", "unstructured": "Millikan R, Dinney C, Swanson D, et al.: Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001, 19:4005\u20134013.", "journal-title": "J Clin Oncol"}, {"key": "104_CR20", "doi-asserted-by": "crossref", "first-page": "439", "DOI": "10.1016/j.ejso.2006.01.018", "volume": "32", "author": "P Mhawech-Fauceglia", "year": "2006", "unstructured": "Mhawech-Fauceglia P, Fischer G, Beck A, et al.: Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006, 32:439\u2013444.", "journal-title": "Eur J Surg Oncol"}, {"key": "104_CR21", "doi-asserted-by": "crossref", "first-page": "570", "DOI": "10.1097/01.ju.0000108845.91485.20", "volume": "171", "author": "JW Slaton", "year": "2004", "unstructured": "Slaton JW, Millikan R, Inoue K, et al.: Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004, 171:570\u2013574.", "journal-title": "J Urol"}, {"key": "104_CR22", "doi-asserted-by": "crossref", "first-page": "1320", "DOI": "10.1093/jnci/94.17.1320", "volume": "94", "author": "S Sen", "year": "2002", "unstructured": "Sen S, Zhou H, Zhang RD, et al.: Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002, 94:1320\u20131329.", "journal-title": "J Natl Cancer Inst"}, {"key": "104_CR23", "doi-asserted-by": "crossref", "first-page": "1401", "DOI": "10.1093/jnci/djn304", "volume": "100", "author": "HS Park", "year": "2008", "unstructured": "Park HS, Park WS, Bondaruk J, et al.: Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008, 100:1401\u20131411.", "journal-title": "J Natl Cancer Inst"}, {"key": "104_CR24", "doi-asserted-by": "crossref", "first-page": "166", "DOI": "10.1093/ajcp/101.2.166", "volume": "101", "author": "PL Nguyen", "year": "1994", "unstructured": "Nguyen PL, Swanson PE, Jaszcz W, et al.: Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994, 101:166\u2013176.", "journal-title": "Am J Clin Pathol"}, {"key": "104_CR25", "doi-asserted-by": "crossref", "first-page": "4671", "DOI": "10.1158/1078-0432.CCR-06-0407", "volume": "12", "author": "KN Blehm", "year": "2006", "unstructured": "Blehm KN, Spiess PE, Bondaruk JE, et al.: Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 2006, 12:4671\u20134677.", "journal-title": "Clin Cancer Res"}, {"key": "104_CR26", "doi-asserted-by": "crossref", "first-page": "1478", "DOI": "10.1158/1078-0432.CCR-07-1593", "volume": "14", "author": "PC Black", "year": "2008", "unstructured": "Black PC, Brown GA, Inamoto T, et al.: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14:1478\u20131486.", "journal-title": "Clin Cancer Res"}, {"key": "104_CR27", "unstructured": "\u2022\u2022 Adam L, Zhong M, Choi W, et al.: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009, 15:5060\u20135072. This recent publication suggests a role for miR-200 as a regulatory mechanism for EMT in urothelial cancer.", "DOI": "10.1158/1078-0432.CCR-08-2245", "doi-asserted-by": "crossref"}, {"key": "104_CR28", "first-page": "2440", "volume": "7", "author": "RE Jimenez", "year": "2001", "unstructured": "Jimenez RE, Hussain M, Bianco FJ Jr, et al.: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001, 7:2440\u20132447.", "journal-title": "Clin Cancer Res"}, {"key": "104_CR29", "first-page": "1189", "volume": "1", "author": "U Lonn", "year": "1995", "unstructured": "Lonn U, Lonn S, Friberg S, et al.: Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995, 1:1189\u20131194.", "journal-title": "Clin Cancer Res"}, {"key": "104_CR30", "first-page": "1317", "volume": "14", "author": "SE Lee", "year": "1994", "unstructured": "Lee SE, Chow NH, Chi YC, et al.: Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res 1994, 14:1317\u20131324.", "journal-title": "Anticancer Res"}, {"key": "104_CR31", "doi-asserted-by": "crossref", "first-page": "379s", "DOI": "10.1200/JCO.2005.02.4448", "volume": "23", "author": "M Hussain", "year": "2005", "unstructured": "Hussain M, Petrylak D, Dunn R, et al.: Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and Gemcitabine (G) in advanced HER2-positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Oncol 2005, 23:379s.", "journal-title": "J Clin Oncol"}, {"key": "104_CR32", "first-page": "2583", "volume": "9", "author": "JC Goddard", "year": "2003", "unstructured": "Goddard JC, Sutton CD, Furness PN, et al.: Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003, 9:2583\u20132586.", "journal-title": "Clin Cancer Res"}, {"key": "104_CR33", "doi-asserted-by": "crossref", "first-page": "1603", "DOI": "10.1093/jnci/87.21.1603", "volume": "87", "author": "BH Bochner", "year": "1995", "unstructured": "Bochner BH, Cote RJ, Weidner N, et al.: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995, 87:1603\u20131612.", "journal-title": "J Natl Cancer Inst"}, {"key": "104_CR34", "first-page": "5281", "volume": "57", "author": "JP Crew", "year": "1997", "unstructured": "Crew JP, O'Brien T, Bradburn M, et al.: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997, 57:5281\u20135285.", "journal-title": "Cancer Res"}, {"key": "104_CR35", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/S1078-1439(03)00015-2", "volume": "22", "author": "CC Yang", "year": "2004", "unstructured": "Yang CC, Chu KC, Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 2004, 22:1\u20136.", "journal-title": "Urol Oncol"}, {"key": "104_CR36", "doi-asserted-by": "crossref", "first-page": "1275", "DOI": "10.1016/S0022-5347(05)65752-7", "volume": "166", "author": "S Bernardini", "year": "2001", "unstructured": "Bernardini S, Fauconnet S, Chabannes E, et al.: Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001, 166:1275\u20131279.", "journal-title": "J Urol"}, {"key": "104_CR37", "doi-asserted-by": "crossref", "first-page": "525", "DOI": "10.1016/j.ymthe.2004.05.027", "volume": "10", "author": "WF Benedict", "year": "2004", "unstructured": "Benedict WF, Tao Z, Kim CS, et al.: Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 2004, 10:525\u2013532.", "journal-title": "Mol Ther"}, {"key": "104_CR38", "doi-asserted-by": "crossref", "first-page": "389", "DOI": "10.1016/j.cytogfr.2007.06.007", "volume": "18", "author": "TL Nagabhushan", "year": "2007", "unstructured": "Nagabhushan TL, Maneval DC, Benedict WF, et al.: Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. Cytokine Growth Factor Rev 2007, 18:389\u2013394.", "journal-title": "Cytokine Growth Factor Rev"}, {"key": "104_CR39", "unstructured": "\u2022\u2022 Sharma P, Shen Y, Wen S, et al.: CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sc U S A 2007, 104:3967\u20133972. This recent tissue-based study suggests the potential impact of tumor recognition by the immune system.", "DOI": "10.1073/pnas.0611618104", "doi-asserted-by": "crossref"}, {"key": "104_CR40", "doi-asserted-by": "crossref", "first-page": "19", "DOI": "10.1186/2051-1426-3-S2-O19", "volume": "3", "author": "P Sharma", "year": "2003", "unstructured": "Sharma P, Gnjatic S, Jungbluth AA, et al.: Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun 2003, 3:19.", "journal-title": "Cancer Immun"}, {"key": "104_CR41", "unstructured": "\u2022\u2022 Sharma P, Bajorin DF, Jungbluth AA, et al.: Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 2008, 31:849\u2013857. This clinical trial uses vaccine to induce immune responses in urothelial cancer patients.", "DOI": "10.1097/CJI.0b013e3181891574", "doi-asserted-by": "crossref"}], "container-title": ["Current Oncology Reports"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s11912-010-0104-5.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s11912-010-0104-5/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s11912-010-0104-5", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 2]], "date-time": "2019-06-02T00:31:37Z", "timestamp": 1559435497000}, "score": 43.54639, "issued": {"date-parts": [[2010, 5, 6]]}, "references-count": 41, "journal-issue": {"published-print": {"date-parts": [[2010, 7]]}, "issue": "4"}, "alternative-id": ["104"], "URL": "http://dx.doi.org/10.1007/s11912-010-0104-5", "relation": {"cites": []}, "ISSN": ["1523-3790", "1534-6269"], "issn-type": [{"value": "1523-3790", "type": "print"}, {"value": "1534-6269", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 20]], "date-time": "2019-12-20T00:02:58Z", "timestamp": 1576800178255}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "5_suppl", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2012, 2, 10]]}, "abstract": "<jats:p> 297 </jats:p><jats:p> Background: PUC are a rare subset of urothelial cancers with a paucity of available literature regarding their clinical behavior. </jats:p><jats:p> Methods: Retrospective analysis of outcomes among all patients (pts) with predominant PUC (pPUC) seen at MDACC from 1999-2010. </jats:p><jats:p> Results: 31 pts with pPUC histology were identified (median age:63.5yrs; 83.3% male; TNM stage:cT1N0,n=4;cT2N0,n=8;cT3b-4aN0,n=6; cT4b, N+ or M+ n = 13). Median survival for all pts was 17.7mo (Stage I-III vs IV: 38.1 vs 13.3mo). Of 18 pts with potentially surgically resectable PUC (&lt;=pT4aN0M0) 7 received neoadjuvant chemotherapy,10 had initial surgery, and one was treated with TURBT alone. Despite pathologic downstaging in 67% of pts treated with neoadjuvant chemotherapy relapses were common and there was no difference in survival between pts treated with neoadjuvant chemotherapy compared to initial surgery, even though adjuvant chemotherapy was given in 7 patients. Only 1 pt in pCR remains in remission &gt;18 mo after surgery. The most common site of recurrence was in the peritoneum (13/18pts), with relapses occurring even in those with pCR at surgery. At least 4 pts developed CNS involvement with lepto-meningeal disease. In pts presenting with metastatic disease who were treated with chemotherapy, the median survival was 12.6 months. </jats:p><jats:p> Conclusions: Plasmacytoid bladder tumors are a very aggressive subset with overall poor outcomes. Though chemotherapy sensitive with downstaging seen with neoadjuvant chemotherapy, there are few long-term survivors. There is a strong predilection for recurrences along the peritoneal lining, and peritoneal carcinomatosis should remain high on a clinician\u2019s differential when patients develop obstructive bowel symptoms. </jats:p>", "DOI": "10.1200/jco.2012.30.5_suppl.297", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T18:53:34Z", "timestamp": 1487876014000}, "page": "297-297", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Incidence of peritoneal carcinomatosis in recurrent plasmacytoid urothelial carcinomas (PUC) of the bladder: A retrospective analysis of patient outcomes at M. D. Anderson Cancer Center (MDACC)."], "prefix": "10.1200", "volume": "30", "author": [{"given": "Farshid", "family": "Dayyani", "sequence": "first", "affiliation": [{"name": "University of Texas M. D. Anderson Cancer Center, Houston, TX"}]}, {"given": "Mark F.", "family": "Munsell", "sequence": "additional", "affiliation": [{"name": "University of Texas M. D. Anderson Cancer Center, Houston, TX"}]}, {"given": "Arlene O.", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": [{"name": "University of Texas M. D. Anderson Cancer Center, Houston, TX"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/jco.2012.30.5_suppl.297", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T21:57:38Z", "timestamp": 1574891858000}, "score": 43.096718, "issued": {"date-parts": [[2012, 2, 10]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2012, 2, 10]]}, "issue": "5_suppl"}, "alternative-id": ["10.1200/jco.2012.30.5_suppl.297"], "URL": "http://dx.doi.org/10.1200/jco.2012.30.5_suppl.297", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T01:04:07Z", "timestamp": 1574211847042}, "reference-count": 62, "publisher": "Informa UK Limited", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Expert Review of Anticancer Therapy"], "published-print": {"date-parts": [[2006, 6]]}, "DOI": "10.1586/14737140.6.6.877", "type": "journal-article", "created": {"date-parts": [[2006, 6, 8]], "date-time": "2006-06-08T16:29:28Z", "timestamp": 1149784168000}, "page": "877-885", "source": "Crossref", "is-referenced-by-count": 9, "title": ["Systemic chemotherapy options for metastatic bladder cancer"], "prefix": "10.1586", "volume": "6", "author": [{"given": "Arlene", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "301", "published-online": {"date-parts": [[2014, 1, 10]]}, "reference": [{"key": "CIT0001", "author": "Sternberg", "volume": "133", "first-page": "403", "year": "1985", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(17)48996-8", "doi-asserted-by": "crossref"}, {"key": "CIT0002", "author": "von der Maase", "volume": "18", "first-page": "3068", "year": "2000", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2000.18.17.3068", "doi-asserted-by": "crossref"}, {"key": "CIT0003", "author": "Sternberg", "volume": "19", "first-page": "2638", "year": "2001", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2001.19.10.2638", "doi-asserted-by": "crossref"}, {"key": "CIT0004", "author": "Logothetis", "volume": "13", "first-page": "2272", "year": "1995", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1995.13.9.2272", "doi-asserted-by": "crossref"}, {"key": "CIT0005", "author": "Seidman", "volume": "11", "first-page": "408", "year": "1993", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1993.11.3.408", "doi-asserted-by": "crossref"}, {"key": "CIT0006", "author": "Loehrer", "volume": "12", "first-page": "483", "year": "1994", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1994.12.3.483", "doi-asserted-by": "crossref"}, {"key": "CIT0007", "author": "Grossman", "volume": "349", "first-page": "859", "year": "2003", "journal-title": "N. Engl. J. Med.", "DOI": "10.1056/NEJMoa022148", "doi-asserted-by": "crossref"}, {"key": "CIT0008", "author": "Millikan", "volume": "19", "first-page": "4005", "year": "2001", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2001.19.20.4005", "doi-asserted-by": "crossref"}, {"key": "CIT0009", "author": "Logothetis", "volume": "8", "first-page": "1050", "year": "1990", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1990.8.6.1050", "doi-asserted-by": "crossref"}, {"key": "CIT0010", "author": "Logothetis", "volume": "14", "first-page": "1265", "year": "1994", "journal-title": "Anticancer Res."}, {"key": "CIT0011", "author": "Siefker-Radtke", "volume": "20", "first-page": "1361", "year": "2002", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.20.5.1361", "doi-asserted-by": "crossref"}, {"key": "CIT0012", "author": "Bamias", "volume": "22", "first-page": "220", "year": "2004", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2004.02.152", "doi-asserted-by": "crossref"}, {"key": "CIT0013", "author": "Bajorin", "volume": "22", "first-page": "211", "year": "2004", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2004.10.988", "doi-asserted-by": "crossref"}, {"key": "CIT0014", "author": "Bajorin", "volume": "17", "first-page": "3173", "year": "1999", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1999.17.10.3173", "doi-asserted-by": "crossref"}, {"key": "CIT0015", "author": "Loehrer", "volume": "10", "first-page": "1066", "year": "1992", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1992.10.7.1066", "doi-asserted-by": "crossref"}, {"key": "CIT0016", "author": "Bellmunt", "volume": "18", "first-page": "3247", "year": "2000", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2000.18.18.3247", "doi-asserted-by": "crossref"}, {"key": "CIT0017", "DOI": "10.1002/cncr.10762", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "author": "Hussain", "volume": "19", "first-page": "2527", "year": "2001", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2001.19.9.2527", "doi-asserted-by": "crossref"}, {"key": "CIT0019", "author": "Bajorin", "volume": "88", "first-page": "1671", "year": "2000", "journal-title": "Cancer", "DOI": "10.1002/(SICI)1097-0142(20000401)88:7<1671::AID-CNCR22>3.0.CO;2-A", "doi-asserted-by": "crossref"}, {"key": "CIT0020", "author": "Millikan", "volume": "92", "first-page": "194", "year": "2001", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(20010701)92:1<194::AID-CNCR1309>3.0.CO;2-3", "doi-asserted-by": "crossref"}, {"key": "CIT0021", "unstructured": "Plunkett W, Ghandi V. Nucleoside analogs: cellular pharmacology, mechanisms of action and strategies for combination therapy. In:Nucleoside Analogs In Cancer Therapy.Cheson BKM, Plunkett W (Eds). Marcel Dekker, Inc., NY, USA 1\u201335 (1997)."}, {"key": "CIT0022", "author": "van Moorsel", "volume": "10", "first-page": "441", "year": "1999", "journal-title": "Ann. Oncol.", "DOI": "10.1023/A:1008301522349", "doi-asserted-by": "crossref"}, {"key": "CIT0023", "author": "Lawrence", "volume": "13", "first-page": "55", "year": "1999", "journal-title": "Oncology"}, {"key": "CIT0024", "author": "Pagliaro", "volume": "20", "first-page": "2965", "year": "2002", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2002.11.114", "doi-asserted-by": "crossref"}, {"key": "CIT0025", "author": "Siefker-Radtke", "volume": "23", "first-page": "391", "year": "2004", "journal-title": "Proc. Am. Soc. Clin. Oncol."}, {"key": "CIT0026", "author": "Dodd", "volume": "18", "first-page": "840", "year": "2000", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2000.18.4.840", "doi-asserted-by": "crossref"}, {"key": "CIT0027", "author": "Maulf", "journal-title": "American Society of Clinical Oncology."}, {"key": "CIT0028", "author": "Thall", "volume": "19", "first-page": "1011", "year": "2000", "journal-title": "Stat. Med.", "DOI": "10.1002/(SICI)1097-0258(20000430)19:8<1011::AID-SIM414>3.0.CO;2-M", "doi-asserted-by": "crossref"}, {"key": "CIT0029", "author": "Hussain", "volume": "91", "first-page": "844", "year": "2004", "journal-title": "Br. J. Cancer", "DOI": "10.1038/sj.bjc.6602112", "doi-asserted-by": "crossref"}, {"key": "CIT0030", "DOI": "10.1016/S0959-8049(01)00295-7", "doi-asserted-by": "publisher"}, {"key": "CIT0031", "author": "Carles", "volume": "59", "first-page": "24", "year": "2000", "journal-title": "Oncology", "DOI": "10.1159/000012132", "doi-asserted-by": "crossref"}, {"key": "CIT0032", "author": "Barbara", "volume": "98", "first-page": "1863", "year": "2003", "journal-title": "Cancer", "DOI": "10.1002/cncr.11726", "doi-asserted-by": "crossref"}, {"key": "CIT0033", "author": "Redman", "volume": "16", "first-page": "1844", "year": "1998", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1998.16.5.1844", "doi-asserted-by": "crossref"}, {"key": "CIT0034", "author": "Small", "volume": "18", "first-page": "2537", "year": "2000", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2000.18.13.2537", "doi-asserted-by": "crossref"}, {"key": "CIT0035", "author": "Dreicer", "volume": "156", "first-page": "1606", "year": "1996", "journal-title": "J. Urol.", "DOI": "10.1016/S0022-5347(01)65459-4", "doi-asserted-by": "crossref"}, {"key": "CIT0036", "author": "Roth", "volume": "12", "first-page": "2264", "year": "1994", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.1994.12.11.2264", "doi-asserted-by": "crossref"}, {"key": "CIT0037", "author": "Chow", "volume": "17", "first-page": "1293", "year": "1997", "journal-title": "Anticancer Res."}, {"key": "CIT0038", "author": "Nguyen", "volume": "101", "first-page": "166", "year": "1994", "journal-title": "Am. J. Clin. Pathol.", "DOI": "10.1093/ajcp/101.2.166", "doi-asserted-by": "crossref"}, {"key": "CIT0039", "author": "Petrylak", "volume": "22", "first-page": "403", "year": "2003", "journal-title": "Proc. Am. Soc. Clin. Oncol."}, {"key": "CIT0040", "author": "Inoue", "volume": "6", "first-page": "4874", "year": "2000", "journal-title": "Clin. Cancer Res."}, {"key": "CIT0041", "author": "Mendelsohn", "volume": "6", "first-page": "747", "year": "2000", "journal-title": "Clin. Cancer Res."}, {"key": "CIT0042", "author": "Bruns", "volume": "60", "first-page": "2926", "year": "2000", "journal-title": "Cancer Res."}, {"key": "CIT0043", "author": "Jimenez", "volume": "7", "first-page": "2440", "year": "2001", "journal-title": "Clin. Cancer Res."}, {"key": "CIT0044", "author": "Korkolopoulou", "volume": "193", "first-page": "767", "year": "1997", "journal-title": "Pathol. Res. Pract.", "DOI": "10.1016/S0344-0338(97)80055-6", "doi-asserted-by": "crossref"}, {"key": "CIT0045", "author": "Lonn", "volume": "1", "first-page": "1189", "year": "1995", "journal-title": "Clin. Cancer Res."}, {"key": "CIT0046", "author": "Lee", "volume": "14", "first-page": "1317", "year": "1994", "journal-title": "Anticancer Res."}, {"key": "CIT0047", "author": "Pegram", "volume": "26", "first-page": "89", "year": "1999", "journal-title": "Semin. Oncol."}, {"key": "CIT0048", "author": "Hussain", "volume": "23", "year": "2005", "journal-title": "J. Clin. Oncol.", "DOI": "10.1200/JCO.2005.02.4448", "doi-asserted-by": "crossref"}, {"key": "CIT0049", "author": "von der Maase", "volume": "18", "first-page": "48", "year": "2004", "journal-title": "Oncology"}, {"key": "CIT0050", "author": "Kamat", "volume": "3", "first-page": "279", "year": "2004", "journal-title": "Mol. Cancer Ther."}, {"key": "CIT0051", "author": "Sridhar", "volume": "23", "year": "2005", "journal-title": "J. Clin. Oncol."}, {"key": "CIT0052", "DOI": "10.1097/01.ju.0000108845.91485.20", "doi-asserted-by": "publisher"}, {"key": "CIT0053", "author": "Cheng", "volume": "101", "first-page": "957", "year": "2004", "journal-title": "Cancer", "DOI": "10.1002/cncr.20456", "doi-asserted-by": "crossref"}, {"key": "CIT0054", "author": "Grignon", "volume": "69", "first-page": "527", "year": "1992", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19920115)69:2<527::AID-CNCR2820690241>3.0.CO;2-7", "doi-asserted-by": "crossref"}, {"key": "CIT0055", "author": "Oesterling", "volume": "65", "first-page": "1928", "year": "1990", "journal-title": "Cancer", "DOI": "10.1002/1097-0142(19900501)65:9<1928::AID-CNCR2820650910>3.0.CO;2-X", "doi-asserted-by": "crossref"}, {"key": "CIT0056", "author": "Quek", "volume": "174", "first-page": "93", "year": "2005", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000162085.20043.1f", "doi-asserted-by": "crossref"}, {"key": "CIT0057", "author": "Siefker-Radtke", "volume": "172", "first-page": "481", "year": "2004", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000132413.85866.fc", "doi-asserted-by": "crossref"}, {"key": "CIT0058", "author": "Lohrisch", "volume": "86", "first-page": "2346", "year": "1999", "journal-title": "Cancer", "DOI": "10.1002/(SICI)1097-0142(19991201)86:11<2346::AID-CNCR24>3.0.CO;2-5", "doi-asserted-by": "crossref"}, {"key": "CIT0059", "author": "Bex", "volume": "65", "first-page": "295", "year": "2005", "journal-title": "Urology", "DOI": "10.1016/j.urology.2004.09.049", "doi-asserted-by": "crossref"}, {"key": "CIT0060", "author": "Abrahams", "volume": "46", "first-page": "57", "year": "2005", "journal-title": "Histopathology", "DOI": "10.1111/j.1365-2559.2004.01980.x", "doi-asserted-by": "crossref"}, {"key": "CIT0061", "author": "Henly", "volume": "42", "first-page": "635", "year": "1993", "journal-title": "Urology", "DOI": "10.1016/0090-4295(93)90526-G", "doi-asserted-by": "crossref"}, {"key": "CIT0062", "author": "Siefker-Radtke", "volume": "169", "first-page": "1295", "year": "2003", "journal-title": "J. Urol.", "DOI": "10.1097/01.ju.0000054646.49381.01", "doi-asserted-by": "crossref"}], "container-title": ["Expert Review of Anticancer Therapy"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1586/14737140.6.6.877", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 19]], "date-time": "2019-04-19T07:49:46Z", "timestamp": 1555660186000}, "score": 42.921947, "issued": {"date-parts": [[2006, 6]]}, "references-count": 62, "journal-issue": {"published-online": {"date-parts": [[2014, 1, 10]]}, "published-print": {"date-parts": [[2006, 6]]}, "issue": "6"}, "alternative-id": ["10.1586/14737140.6.6.877"], "URL": "http://dx.doi.org/10.1586/14737140.6.6.877", "relation": {"cites": []}, "ISSN": ["1473-7140", "1744-8328"], "issn-type": [{"value": "1473-7140", "type": "print"}, {"value": "1744-8328", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T17:13:57Z", "timestamp": 1574788437261}, "reference-count": 42, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Cancer Journal"], "published-print": {"date-parts": [[2016]]}, "DOI": "10.1097/ppo.0000000000000175", "type": "journal-article", "created": {"date-parts": [[2016, 4, 22]], "date-time": "2016-04-22T13:06:38Z", "timestamp": 1461330398000}, "page": "96-100", "source": "Crossref", "is-referenced-by-count": 2, "title": ["The State of Immune Checkpoint Inhibition in Urothelial Carcinoma"], "prefix": "10.1097", "volume": "22", "author": [{"given": "Matthew T.", "family": "Campbell", "sequence": "first", "affiliation": []}, {"given": "Arlene O.", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}, {"given": "Jianjun", "family": "Gao", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["The Cancer Journal"], "language": "en", "deposited": {"date-parts": [[2019, 9, 6]], "date-time": "2019-09-06T23:30:55Z", "timestamp": 1567812655000}, "score": 42.07051, "subtitle": ["Current Evidence and Future Areas of Exploration"], "issued": {"date-parts": [[2016]]}, "references-count": 42, "journal-issue": {"issue": "2"}, "URL": "http://dx.doi.org/10.1097/ppo.0000000000000175", "ISSN": ["1528-9117"], "issn-type": [{"value": "1528-9117", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T15:43:11Z", "timestamp": 1574869391371}, "reference-count": 115, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 12, 5]], "date-time": "2017-12-05T00:00:00Z", "timestamp": 1512432000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Nat Rev Urol"], "published-print": {"date-parts": [[2018, 2]]}, "DOI": "10.1038/nrurol.2017.190", "type": "journal-article", "created": {"date-parts": [[2017, 12, 5]], "date-time": "2017-12-05T10:40:58Z", "timestamp": 1512470458000}, "page": "112-124", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 19, "title": ["Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition"], "prefix": "10.1038", "volume": "15", "author": [{"given": "Arlene", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}, {"given": "Brendan", "family": "Curti", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 12, 5]]}, "reference": [{"key": "BFnrurol2017190_CR1", "doi-asserted-by": "publisher", "first-page": "1505", "DOI": "10.1002/(SICI)1097-0142(19961001)78:7<1505::AID-CNCR19>3.0.CO;2-3", "volume": "78", "author": "NE Fleshner", "year": "1996", "unstructured": "Fleshner, N. E.  et al. The national cancer data base report on bladder carcinoma. The American College of Surgeons commission on cancer and the American Cancer Society. Cancer 78, 1505\u20131513 (1996).", "journal-title": "Cancer"}, {"key": "BFnrurol2017190_CR2", "doi-asserted-by": "publisher", "first-page": "7", "DOI": "10.3322/caac.21387", "volume": "67", "author": "RL Siegel", "year": "2017", "unstructured": "Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7\u201330 (2017).", "journal-title": "CA Cancer J. Clin."}, {"key": "BFnrurol2017190_CR3", "unstructured": "National Cancer Institute. Cancer stat facts: bladder cancer. National Cancer Institute \n                    http://seer.cancer.gov/statfacts/html/urinb.html\n                    \n                   (2016)."}, {"key": "BFnrurol2017190_CR4", "doi-asserted-by": "publisher", "first-page": "1050", "DOI": "10.1200/JCO.1990.8.6.1050", "volume": "8", "author": "CJ Logothetis", "year": "1990", "unstructured": "Logothetis, C. J.  et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050\u20131055 (1990).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR5", "doi-asserted-by": "publisher", "first-page": "2638", "DOI": "10.1200/JCO.2001.19.10.2638", "volume": "19", "author": "CN Sternberg", "year": "2001", "unstructured": "Sternberg, C. N.  et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19, 2638\u20132646 (2001).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR6", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1007/s00345-015-1636-y", "volume": "34", "author": "EE van de Putte", "year": "2016", "unstructured": "van de Putte, E. E.  et al. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J. Urol. 34, 157\u2013162 (2016).", "journal-title": "World J. Urol."}, {"key": "BFnrurol2017190_CR7", "doi-asserted-by": "publisher", "first-page": "506", "DOI": "10.1002/cncr.22031", "volume": "107", "author": "A Dash", "year": "2006", "unstructured": "Dash, A.  et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506\u2013513 (2006).", "journal-title": "Cancer"}, {"key": "BFnrurol2017190_CR8", "doi-asserted-by": "publisher", "first-page": "71", "DOI": "10.1016/j.clgc.2013.11.016", "volume": "12", "author": "G Sonpavde", "year": "2014", "unstructured": "Sonpavde, G., Galsky, M. D., Latini, D. & Chen, G. J. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. Clin. Genitourin. Cancer 12, 71\u201373 (2014).", "journal-title": "Clin. Genitourin. Cancer"}, {"key": "BFnrurol2017190_CR9", "doi-asserted-by": "publisher", "first-page": "1107", "DOI": "10.1200/JCO.2011.38.6979", "volume": "30", "author": "J Bellmunt", "year": "2012", "unstructured": "Bellmunt, J.  et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J. Clin. Oncol. 30, 1107\u20131113 (2012).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR10", "doi-asserted-by": "publisher", "first-page": "4602", "DOI": "10.1200/JCO.2005.07.757", "volume": "23", "author": "H von der Maase", "year": "2005", "unstructured": "von der Maase, H.  et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602\u20134608 (2005).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR11", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.1200/JCO.1997.15.5.1853", "volume": "15", "author": "JA McCaffrey", "year": "1997", "unstructured": "McCaffrey, J. A.  et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. 15, 1853\u20131857 (1997).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR12", "doi-asserted-by": "publisher", "first-page": "1466", "DOI": "10.1093/annonc/mdt007", "volume": "24", "author": "J Bellmunt", "year": "2013", "unstructured": "Bellmunt, J.  et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol. 24, 1466\u20131472 (2013).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR13", "doi-asserted-by": "publisher", "first-page": "3967", "DOI": "10.1073/pnas.0611618104", "volume": "104", "author": "P Sharma", "year": "2007", "unstructured": "Sharma, P.  et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc. Natl Acad. Sci. USA 104, 3967\u20133972 (2007).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrurol2017190_CR14", "doi-asserted-by": "publisher", "first-page": "214", "DOI": "10.1038/nature12213", "volume": "499", "author": "MS Lawrence", "year": "2013", "unstructured": "Lawrence, M. S.  et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218 (2013).", "journal-title": "Nature"}, {"key": "BFnrurol2017190_CR15", "unstructured": "The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).", "DOI": "10.1038/nature12965", "doi-asserted-by": "crossref"}, {"key": "BFnrurol2017190_CR16", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1038/nrurol.2014.15", "volume": "11", "author": "G Redelman-Sidi", "year": "2014", "unstructured": "Redelman-Sidi, G., Glickman, M. S. & Bochner, B. H. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat. Rev. Urol. 11, 153\u2013162 (2014).", "journal-title": "Nat. Rev. Urol."}, {"key": "BFnrurol2017190_CR17", "doi-asserted-by": "publisher", "first-page": "446", "DOI": "10.6004/jnccn.2013.0059", "volume": "11", "author": "PE Clark", "year": "2013", "unstructured": "Clark, P. E.  et al. Bladder cancer. J. Natl Compr. Canc. Netw. 11, 446\u2013475 (2013).", "journal-title": "J. Natl Compr. Canc. Netw."}, {"key": "BFnrurol2017190_CR18", "doi-asserted-by": "publisher", "first-page": "354", "DOI": "10.1016/S1078-1439(03)00012-7", "volume": "21", "author": "JS Lam", "year": "2003", "unstructured": "Lam, J. S.  et al. Bacillus calmete-guerin plus interferon-\u03b12B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol. Oncol. 21, 354\u2013360 (2003).", "journal-title": "Urol. Oncol."}, {"key": "BFnrurol2017190_CR19", "doi-asserted-by": "publisher", "first-page": "1361", "DOI": "10.1200/JCO.2002.20.5.1361", "volume": "20", "author": "AO Siefker-Radtke", "year": "2002", "unstructured": "Siefker-Radtke, A. O.  et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J. Clin. Oncol. 20, 1361\u20131367 (2002).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR20", "doi-asserted-by": "publisher", "first-page": "1189", "DOI": "10.1016/j.juro.2016.12.090", "volume": "197", "author": "R Chou", "year": "2017", "unstructured": "Chou, R.  et al. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J. Urol. 197, 1189\u20131199 (2017).", "journal-title": "J. Urol."}, {"key": "BFnrurol2017190_CR21", "doi-asserted-by": "publisher", "first-page": "703", "DOI": "10.1016/j.urology.2014.10.020", "volume": "85", "author": "SF Faraj", "year": "2015", "unstructured": "Faraj, S. F.  et al. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 85, 703\u2013706 (2015).", "journal-title": "Urology"}, {"key": "BFnrurol2017190_CR22", "doi-asserted-by": "publisher", "first-page": "1499", "DOI": "10.1002/cncr.22588", "volume": "109", "author": "BA Inman", "year": "2007", "unstructured": "Inman, B. A.  et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109, 1499\u20131505 (2007).", "journal-title": "Cancer"}, {"key": "BFnrurol2017190_CR23", "doi-asserted-by": "publisher", "first-page": "166", "DOI": "10.1111/j.1600-065X.2008.00662.x", "volume": "224", "author": "BT Fife", "year": "2008", "unstructured": "Fife, B. T. & Bluestone, J. A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224, 166\u2013182 (2008).", "journal-title": "Immunol. Rev."}, {"key": "BFnrurol2017190_CR24", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1016/S0378-1119(97)00260-6", "volume": "197", "author": "LR Finger", "year": "1997", "unstructured": "Finger, L. R.  et al. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 197, 177\u2013187 (1997).", "journal-title": "Gene"}, {"key": "BFnrurol2017190_CR25", "doi-asserted-by": "publisher", "first-page": "74", "DOI": "10.1186/1756-8722-6-74", "volume": "6", "author": "L Shi", "year": "2013", "unstructured": "Shi, L., Chen, S., Yang, L. & Li, Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J. Hematol. Oncol. 6, 74 (2013).", "journal-title": "J. Hematol. Oncol."}, {"key": "BFnrurol2017190_CR26", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1093/intimm/dxs098", "volume": "25", "author": "ML Thibult", "year": "2013", "unstructured": "Thibult, M. L.  et al. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 25, 129\u2013137 (2013).", "journal-title": "Int. Immunol."}, {"key": "BFnrurol2017190_CR27", "doi-asserted-by": "publisher", "first-page": "328rv4", "DOI": "10.1126/scitranslmed.aad7118", "volume": "8", "author": "W Zou", "year": "2016", "unstructured": "Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).", "journal-title": "Sci. Transl. Med."}, {"key": "BFnrurol2017190_CR28", "doi-asserted-by": "publisher", "first-page": "550", "DOI": "10.3389/fimmu.2016.00550", "volume": "7", "author": "K Bardhan", "year": "2016", "unstructured": "Bardhan, K., Anagnostou, T. & Boussiotis, V. A. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front. Immunol. 7, 550 (2016).", "journal-title": "Front. Immunol."}, {"key": "BFnrurol2017190_CR29", "doi-asserted-by": "publisher", "first-page": "793", "DOI": "10.1038/nm730", "volume": "8", "author": "H Dong", "year": "2002", "unstructured": "Dong, H.  et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793\u2013800 (2002).", "journal-title": "Nat. Med."}, {"key": "BFnrurol2017190_CR30", "doi-asserted-by": "publisher", "first-page": "261", "DOI": "10.1038/85330", "volume": "2", "author": "Y Latchman", "year": "2001", "unstructured": "Latchman, Y.  et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261\u2013268 (2001).", "journal-title": "Nat. Immunol."}, {"key": "BFnrurol2017190_CR31", "doi-asserted-by": "publisher", "first-page": "397", "DOI": "10.1016/S1357-4310(98)01322-7", "volume": "4", "author": "B Agrawal", "year": "1998", "unstructured": "Agrawal, B., Gendler, S. J. & Longenecker, B. M. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol. Med. Today 4, 397\u2013403 (1998).", "journal-title": "Mol. Med. Today"}, {"key": "BFnrurol2017190_CR32", "doi-asserted-by": "publisher", "first-page": "784", "DOI": "10.4049/jimmunol.1001562", "volume": "186", "author": "G Driessens", "year": "2011", "unstructured": "Driessens, G.  et al. \u03b2-Catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-\u03b31 phosphorylation. J. Immunol. 186, 784\u2013790 (2011).", "journal-title": "J. Immunol."}, {"key": "BFnrurol2017190_CR33", "doi-asserted-by": "publisher", "first-page": "841", "DOI": "10.1007/s00262-017-1983-1", "volume": "66", "author": "MR Dunne", "year": "2017", "unstructured": "Dunne, M. R.  et al. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients. Cancer Immunol. Immunother. 66, 841\u2013850 (2017).", "journal-title": "Cancer Immunol. Immunother."}, {"key": "BFnrurol2017190_CR34", "doi-asserted-by": "publisher", "first-page": "412", "DOI": "10.1158/2326-6066.CIR-14-0150", "volume": "3", "author": "T Kouo", "year": "2015", "unstructured": "Kouo, T.  et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol. Res. 3, 412\u2013423 (2015).", "journal-title": "Cancer Immunol. Res."}, {"key": "BFnrurol2017190_CR35", "first-page": "3164", "volume": "51", "author": "F Pandolfi", "year": "1991", "unstructured": "Pandolfi, F.  et al. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 51, 3164\u20133170 (1991).", "journal-title": "Cancer Res."}, {"key": "BFnrurol2017190_CR36", "doi-asserted-by": "publisher", "first-page": "5839", "DOI": "10.1158/0008-5472.CAN-04-0465", "volume": "64", "author": "PC Rodriguez", "year": "2004", "unstructured": "Rodriguez, P. C.  et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839\u20135849 (2004).", "journal-title": "Cancer Res."}, {"key": "BFnrurol2017190_CR37", "doi-asserted-by": "publisher", "first-page": "2335", "DOI": "10.3892/or.2014.3544", "volume": "32", "author": "YS Shan", "year": "2014", "unstructured": "Shan, Y. S.  et al. Suppression of mucin 2 promotes interleukin-6 secretion and tumor growth in an orthotopic immune-competent colon cancer animal model. Oncol. Rep. 32, 2335\u20132342 (2014).", "journal-title": "Oncol. Rep."}, {"key": "BFnrurol2017190_CR38", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1158/2326-6066.CIR-15-0274", "volume": "4", "author": "RF Sweis", "year": "2016", "unstructured": "Sweis, R. F.  et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4, 563\u2013568 (2016).", "journal-title": "Cancer Immunol. Res."}, {"key": "BFnrurol2017190_CR39", "doi-asserted-by": "publisher", "first-page": "162", "DOI": "10.1038/nri2506", "volume": "9", "author": "DI Gabrilovich", "year": "2009", "unstructured": "Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).", "journal-title": "Nat. Rev. Immunol."}, {"issue": "Suppl. 15", "key": "BFnrurol2017190_CR40", "doi-asserted-by": "publisher", "first-page": "4500", "DOI": "10.1200/jco.2015.33.15_suppl.4500", "volume": "33", "author": "TK Choueiri", "year": "2015", "unstructured": "Choueiri, T. K.  et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes [abstract]. J. Clin. Oncol. 33 (Suppl. 15), 4500 (2015).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR41", "doi-asserted-by": "publisher", "first-page": "252", "DOI": "10.1038/nrc3239", "volume": "12", "author": "DM Pardoll", "year": "2012", "unstructured": "Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).", "journal-title": "Nat. Rev. Cancer"}, {"key": "BFnrurol2017190_CR42", "doi-asserted-by": "publisher", "first-page": "1154", "DOI": "10.1038/modpathol.2015.63", "volume": "28", "author": "J Koh", "year": "2015", "unstructured": "Koh, J.  et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod. Pathol. 28, 1154\u20131166 (2015).", "journal-title": "Mod. Pathol."}, {"key": "BFnrurol2017190_CR43", "doi-asserted-by": "publisher", "first-page": "e87705", "DOI": "10.1371/journal.pone.0087705", "volume": "9", "author": "AA Tarhini", "year": "2014", "unstructured": "Tarhini, A. A.  et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE 9, e87705 (2014).", "journal-title": "PLoS ONE"}, {"key": "BFnrurol2017190_CR44", "doi-asserted-by": "publisher", "first-page": "2861", "DOI": "10.1158/1078-0432.CCR-10-0569", "volume": "16", "author": "BC Carthon", "year": "2010", "unstructured": "Carthon, B. C.  et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861\u20132871 (2010).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrurol2017190_CR45", "doi-asserted-by": "publisher", "first-page": "14987", "DOI": "10.1073/pnas.0806075105", "volume": "105", "author": "CI Liakou", "year": "2008", "unstructured": "Liakou, C. I.  et al. CTLA-4 blockade increases IFN\u03b3-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987\u201314992 (2008).", "journal-title": "Proc. Natl Acad. Sci. USA"}, {"key": "BFnrurol2017190_CR46", "doi-asserted-by": "publisher", "first-page": "1909", "DOI": "10.1016/S0140-6736(16)00561-4", "volume": "387", "author": "JE Rosenberg", "year": "2016", "unstructured": "Rosenberg, J. E.  et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).", "journal-title": "Lancet"}, {"issue": "Suppl. 6", "key": "BFnrurol2017190_CR47", "first-page": "783P", "volume": "27", "author": "Y Loriot", "year": "2016", "unstructured": "Loriot, Y.  et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the phase II IMvigor210 study. Ann. Oncol. 27 (Suppl. 6), 783P (2016).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR48", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1016/S0140-6736(16)32455-2", "volume": "389", "author": "AV Balar", "year": "2017", "unstructured": "Balar, A. V.  et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67\u201376 (2017).", "journal-title": "Lancet"}, {"key": "BFnrurol2017190_CR49", "doi-asserted-by": "publisher", "first-page": "1590", "DOI": "10.1016/S1470-2045(16)30496-X", "volume": "17", "author": "P Sharma", "year": "2016", "unstructured": "Sharma, P.  et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 17, 1590\u20131598 (2016).", "journal-title": "Lancet Oncol."}, {"key": "BFnrurol2017190_CR50", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1016/S0140-6736(16)32455-2", "volume": "389", "author": "P Sharma", "year": "2017", "unstructured": "Sharma, P.  et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 389, 67\u201376 (2017).", "journal-title": "Lancet Oncol."}, {"key": "BFnrurol2017190_CR51", "doi-asserted-by": "publisher", "first-page": "3119", "DOI": "10.1200/JCO.2016.67.9761", "volume": "34", "author": "C Massard", "year": "2016", "unstructured": "Massard, C.  et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119\u20133125 (2016).", "journal-title": "J. Clin. Oncol."}, {"issue": "Suppl. 7", "key": "BFnrurol2017190_CR52", "doi-asserted-by": "publisher", "first-page": "4502", "DOI": "10.1200/jco.2015.33.15_suppl.4502", "volume": "33", "author": "ER Plimack", "year": "2015", "unstructured": "Plimack, E. R.  et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012 [abstract]. J. Clin. Oncol. 33 (Suppl. 7), 4502 (2015).", "journal-title": "J. Clin. Oncol."}, {"issue": "Suppl. 7", "key": "BFnrurol2017190_CR53", "doi-asserted-by": "publisher", "first-page": "TPS4571", "DOI": "10.1200/jco.2015.33.15_suppl.tps4571", "volume": "33", "author": "J Bellmunt", "year": "2015", "unstructured": "Bellmunt, J.  et al. KEYNOTE-045: randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer [abstract]. J. Clin. Oncol. 33 (Suppl. 7), TPS4571 (2015).", "journal-title": "J. Clin. Oncol."}, {"issue": "Suppl. 6", "key": "BFnrurol2017190_CR54", "first-page": "LBA32_PR", "volume": "27", "author": "A Balar", "year": "2016", "unstructured": "Balar, A.  et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 keynote-052 study. Ann. Oncol. 27 (Suppl. 6), LBA32_PR (2016).", "journal-title": "Ann. Oncol."}, {"issue": "Suppl. 6", "key": "BFnrurol2017190_CR55", "first-page": "777PD", "volume": "27", "author": "M Patel", "year": "2016", "unstructured": "Patel, M.  et al. Avelumab (MSB0010718C; anti\u2013PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible. Ann. Oncol. 27 (Suppl. 6), 777PD (2016).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR56", "unstructured": "Sharma, P.  et al. Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial cancer: first results from the phase I/II checkmate 032 study society for immunotherapy of cancer (SITC) annual meeting. National Harbor (in the press)."}, {"issue": "Suppl. 6", "key": "BFnrurol2017190_CR57", "first-page": "774PD", "volume": "27", "author": "AB Apolo", "year": "2016", "unstructured": "Apolo, A. B.  et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Ann. Oncol. 27 (Suppl. 6), 774PD (2016).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR58", "unstructured": "Bristol-Myers Squibb. Latest News. Bristol-Myers Squibb \n                    https://investors.bms.com/iframes/press-releases/press-release-details/2016/Bristol-Myers-Squibb-and-Calithera-Biosciences-Announce-Clinical-Collaboration-to-Evaluate-Opdivo-nivolumab-in-Combination-with-CB-839-in-Clear-Cell-Renal-Cell-Carcinoma/default.aspx\n                    \n                   (2016)."}, {"issue": "Suppl. 15", "key": "BFnrurol2017190_CR59", "doi-asserted-by": "publisher", "first-page": "TPS4574", "DOI": "10.1200/JCO.2016.34.15_suppl.TPS4574", "volume": "34", "author": "T Powles", "year": "2016", "unstructured": "Powles, T.  et al. A phase 3 study of first-line durvalumab (MEDI4736) \u00b1 tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE [abstract]. J. Clin. Oncol. 34 (Suppl. 15), TPS4574 (2016).", "journal-title": "J. Clin. Oncol."}, {"issue": "Suppl. 6", "key": "BFnrurol2017190_CR60", "first-page": "1050PD", "volume": "27", "author": "O Hamid", "year": "2016", "unstructured": "Hamid, O.  et al. Combination of an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: a phase 1, open-label study in advanced malignancies. Ann. Oncol. 27 (Suppl. 6), 1050PD (2016).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR61", "doi-asserted-by": "publisher", "first-page": "5532", "DOI": "10.1038/s41598-017-06002-8", "volume": "7", "author": "HT Lee", "year": "2017", "unstructured": "Lee, H. T.  et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci. Rep. 7, 5532 (2017).", "journal-title": "Sci. Rep."}, {"key": "BFnrurol2017190_CR62", "doi-asserted-by": "publisher", "first-page": "558", "DOI": "10.1038/nature13904", "volume": "515", "author": "T Powles", "year": "2014", "unstructured": "Powles, T.  et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558\u2013562 (2014).", "journal-title": "Nature"}, {"key": "BFnrurol2017190_CR63", "unstructured": "Genetech. TECENTRIQ prescribing information. Genetech \n                    https://www.gene.com/download/pdf/tecentriq_prescribing.pdf\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR64", "unstructured": "US National Library of Medicine. ClinicalTrials.gov \n                    https://clinicaltrials.gov/ct2/show/NCT02302807?term=NCT02302807&rank=1\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR65", "unstructured": "Roche. Roche provides update on phase III study of TECENTRIQ\u00ae (atezolizumab) in people with previously treated advanced bladder cancer. Roche \n                    http://www.roche.com/media/store/releases/med-cor-2017-05-10.htm\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR66", "doi-asserted-by": "publisher", "first-page": "846", "DOI": "10.1158/2326-6066.CIR-14-0040", "volume": "2", "author": "C Wang", "year": "2014", "unstructured": "Wang, C.  et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2, 846\u2013856 (2014).", "journal-title": "Cancer Immunol. Res."}, {"key": "BFnrurol2017190_CR67", "unstructured": "Bristol-Myers Squibb. OPDIVO (nivolumab) prescribing information. Bristol-Myers Squibb \n                    https://packageinserts.bms.com/pi/pi_opdivo.pdf\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR68", "doi-asserted-by": "publisher", "first-page": "320", "DOI": "10.1056/NEJMoa1412082", "volume": "372", "author": "C Robert", "year": "2015", "unstructured": "Robert, C.  et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR69", "doi-asserted-by": "publisher", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "volume": "373", "author": "H Borghaei", "year": "2015", "unstructured": "Borghaei, H.  et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627\u20131639 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR70", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "volume": "373", "author": "J Brahmer", "year": "2015", "unstructured": "Brahmer, J.  et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR71", "unstructured": "[No authors listed.] Nivolumab doubles survival for patients with HNSCC. Cancer Discov. 6, OF3 (2016).", "DOI": "10.1158/2159-8290.CD-NB2016-049", "doi-asserted-by": "crossref"}, {"key": "BFnrurol2017190_CR72", "doi-asserted-by": "publisher", "first-page": "1430", "DOI": "10.1200/JCO.2014.59.0703", "volume": "33", "author": "RJ Motzer", "year": "2015", "unstructured": "Motzer, R. J.  et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33, 1430\u20131437 (2015).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR73", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1056/NEJMoa1411087", "volume": "372", "author": "SM Ansell", "year": "2015", "unstructured": "Ansell, S. M.  et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).", "journal-title": "N. Engl. J. Med."}, {"issue": "Suppl. 15", "key": "BFnrurol2017190_CR74", "doi-asserted-by": "publisher", "first-page": "3501", "DOI": "10.1200/JCO.2016.34.15_suppl.3501", "volume": "34", "author": "MJ Overman", "year": "2016", "unstructured": "Overman, M. J.  et al. Nivolumab \u00b1 ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results [abstract]. J. Clin. Oncol. 34 (Suppl. 15), 3501 (2016).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR75", "doi-asserted-by": "publisher", "first-page": "2492", "DOI": "10.1016/S0140-6736(17)31046-2", "volume": "389", "author": "AB El-Khoueiry", "year": "2017", "unstructured": "El-Khoueiry, A. B.  et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492\u20132502 (2017).", "journal-title": "Lancet"}, {"key": "BFnrurol2017190_CR76", "unstructured": "US Food and Drug Administration. Imfinzi (durvalumab) prescribing information. FDA \n                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR77", "doi-asserted-by": "publisher", "first-page": "2117", "DOI": "10.1200/JCO.2016.71.6795", "volume": "35", "author": "AB Apolo", "year": "2017", "unstructured": "Apolo, A. B.  et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J. Clin. Oncol. 35, 2117\u20132124 (2017).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR78", "unstructured": "US Food and Drug Administration. Bavencio (avelumab) prescribing information. FDA \n                    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR79", "doi-asserted-by": "publisher", "first-page": "1148", "DOI": "10.1158/2326-6066.CIR-15-0059", "volume": "3", "author": "B Boyerinas", "year": "2015", "unstructured": "Boyerinas, B.  et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res. 3, 1148\u20131157 (2015).", "journal-title": "Cancer Immunol. Res."}, {"key": "BFnrurol2017190_CR80", "doi-asserted-by": "publisher", "first-page": "1015", "DOI": "10.1056/NEJMoa1613683", "volume": "376", "author": "J Bellmunt", "year": "2017", "unstructured": "Bellmunt, J.  et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR81", "unstructured": "Merck. Keytruda (pembrolizumab) prescribing information. Merck \n                    https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR82", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1056/NEJMoa1504030", "volume": "373", "author": "J Larkin", "year": "2015", "unstructured": "Larkin, J.  et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR83", "doi-asserted-by": "publisher", "first-page": "299", "DOI": "10.1016/S1470-2045(15)00544-6", "volume": "17", "author": "S Antonia", "year": "2016", "unstructured": "Antonia, S.  et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17, 299\u2013308 (2016).", "journal-title": "Lancet Oncol."}, {"key": "BFnrurol2017190_CR84", "unstructured": "Hammers, H. J.  et al. Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): the CheckMate 016 study. J. Clin. Oncol. \n                    http://dx.doi.org/10.1200/JCO.2016.72.1985\n                    \n                   (2017).", "DOI": "10.1200/JCO.2016.72.1985", "doi-asserted-by": "crossref"}, {"key": "BFnrurol2017190_CR85", "doi-asserted-by": "publisher", "first-page": "122", "DOI": "10.1056/NEJMoa1302369", "volume": "369", "author": "JD Wolchok", "year": "2013", "unstructured": "Wolchok, J. D.  et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR86", "unstructured": "US National Library of Medicine. ClinicalTrials.gov \n                    https://clinicaltrials.gov/ct2/show/NCT03036098\n                    \n                   (2017)."}, {"issue": "Suppl. 15", "key": "BFnrurol2017190_CR87", "doi-asserted-by": "publisher", "first-page": "TPS4578", "DOI": "10.1200/JCO.2016.34.15_suppl.TPS4578", "volume": "34", "author": "CJ Hoimes", "year": "2016", "unstructured": "Hoimes, C. J.  et al. Hcrn GU14-188: neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC) [abstract]. J. Clin. Oncol. 34 (Suppl. 15), TPS4578 (2016).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR88", "unstructured": "US National Library of Medicine. ClinicalTrials.gov \n                    https://clinicaltrials.gov/ct2/show/NCT02178722\n                    \n                   (2017)."}, {"key": "BFnrurol2017190_CR89", "doi-asserted-by": "publisher", "first-page": "2691", "DOI": "10.1200/JCO.2012.41.6750", "volume": "30", "author": "JS Weber", "year": "2012", "unstructured": "Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691\u20132697 (2012).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR90", "doi-asserted-by": "publisher", "first-page": "785", "DOI": "10.1200/JCO.2015.66.1389", "volume": "35", "author": "JS Weber", "year": "2017", "unstructured": "Weber, J. S.  et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785\u2013792 (2017).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR91", "doi-asserted-by": "publisher", "first-page": "317", "DOI": "10.1002/phar.1714", "volume": "36", "author": "PJ Medina", "year": "2016", "unstructured": "Medina, P. J. & Adams, V. R. PD-1 pathway inhibitors: Immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy 36, 317\u2013334 (2016).", "journal-title": "Pharmacotherapy"}, {"key": "BFnrurol2017190_CR92", "first-page": "2375", "volume": "26", "author": "J Naidoo", "year": "2015", "unstructured": "Naidoo, J.  et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375\u20132391 (2015).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR93", "doi-asserted-by": "publisher", "first-page": "10391", "DOI": "10.1038/ncomms10391", "volume": "7", "author": "K Dubin", "year": "2016", "unstructured": "Dubin, K.  et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).", "journal-title": "Nat. Commun."}, {"key": "BFnrurol2017190_CR94", "first-page": "560", "volume": "4", "author": "J Villadolid", "year": "2015", "unstructured": "Villadolid, J. & Amin, A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 4, 560\u2013575 (2015).", "journal-title": "Transl Lung Cancer Res."}, {"key": "BFnrurol2017190_CR95", "doi-asserted-by": "publisher", "first-page": "1230", "DOI": "10.1634/theoncologist.2016-0055", "volume": "21", "author": "JS Weber", "year": "2016", "unstructured": "Weber, J. S., Postow, M., Lao, C. D. & Schadendorf, D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist 21, 1230\u20131240 (2016).", "journal-title": "Oncologist"}, {"key": "BFnrurol2017190_CR96", "doi-asserted-by": "publisher", "first-page": "193", "DOI": "10.1007/s11739-009-0342-4", "volume": "5", "author": "S Mancini", "year": "2010", "unstructured": "Mancini, S., Amorotti, E., Vecchio, S., Ponz de Leon, M. & Roncucci, L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern. Emerg. Med. 5, 193\u2013200 (2010).", "journal-title": "Intern. Emerg. Med."}, {"key": "BFnrurol2017190_CR97", "doi-asserted-by": "publisher", "first-page": "806", "DOI": "10.1177/1060028014528152", "volume": "48", "author": "SP Merrill", "year": "2014", "unstructured": "Merrill, S. P.  et al. Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann. Pharmacother. 48, 806\u2013810 (2014).", "journal-title": "Ann. Pharmacother."}, {"key": "BFnrurol2017190_CR98", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1097/CMR.0b013e32835fb524", "volume": "23", "author": "C Pages", "year": "2013", "unstructured": "Pages, C.  et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 23, 227\u2013230 (2013).", "journal-title": "Melanoma Res."}, {"key": "BFnrurol2017190_CR99", "unstructured": "Kim, C., Gao, J., Shannon, V. R. & Siefker-Radtke, A. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep. \n                    http://dx.doi.org/10.1136/bcr-2016-216217\n                    \n                   (2016).", "DOI": "10.1136/bcr-2016-216217", "doi-asserted-by": "crossref"}, {"key": "BFnrurol2017190_CR100", "doi-asserted-by": "publisher", "first-page": "368", "DOI": "10.1016/j.eururo.2017.03.037", "volume": "72", "author": "B Escudier", "year": "2017", "unstructured": "Escudier, B.  et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur. Urol. 72, 368\u2013376 (2017).", "journal-title": "Eur. Urol."}, {"key": "BFnrurol2017190_CR101", "doi-asserted-by": "publisher", "first-page": "7412", "DOI": "10.1158/1078-0432.CCR-09-1624", "volume": "15", "author": "JD Wolchok", "year": "2009", "unstructured": "Wolchok, J. D.  et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrurol2017190_CR102", "doi-asserted-by": "publisher", "first-page": "1510", "DOI": "10.1200/JCO.2015.64.0391", "volume": "34", "author": "FS Hodi", "year": "2016", "unstructured": "Hodi, F. S.  et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34, 1510\u20131517 (2016).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR103", "doi-asserted-by": "publisher", "first-page": "1803", "DOI": "10.1056/NEJMoa1510665", "volume": "373", "author": "RJ Motzer", "year": "2015", "unstructured": "Motzer, R. J.  et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803\u20131813 (2015).", "journal-title": "N. Engl. J. Med."}, {"key": "BFnrurol2017190_CR104", "doi-asserted-by": "publisher", "first-page": "3541", "DOI": "10.1200/JCO.2015.61.6870", "volume": "33", "author": "VL Chiou", "year": "2015", "unstructured": "Chiou, V. L. & Burotto, M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541\u20133543 (2015).", "journal-title": "J. Clin. Oncol."}, {"key": "BFnrurol2017190_CR105", "unstructured": "Imafuku, K., Hata, H., Kitamura, S., Yanagi, T. & Shimizu, H. Ultrasonographic findings can identify 'pseudoprogression' under nivolumab therapy. Br. J. Dermatol. \n                    http://dx.doi.org/10.1111/bjd.15198\n                    \n                   (2016).", "DOI": "10.1111/bjd.15198", "doi-asserted-by": "crossref"}, {"key": "BFnrurol2017190_CR106", "doi-asserted-by": "publisher", "first-page": "1920", "DOI": "10.1158/1078-0432.CCR-16-1741", "volume": "23", "author": "S Champiat", "year": "2017", "unstructured": "Champiat, S.  et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res. 23, 1920\u20131928 (2017).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrurol2017190_CR107", "doi-asserted-by": "publisher", "first-page": "1605", "DOI": "10.1093/annonc/mdx178", "volume": "28", "author": "E Saada-Bouzid", "year": "2017", "unstructured": "Saada-Bouzid, E.  et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol. 28, 1605\u20131611 (2017).", "journal-title": "Ann. Oncol."}, {"key": "BFnrurol2017190_CR108", "doi-asserted-by": "publisher", "first-page": "4242", "DOI": "10.1158/1078-0432.CCR-16-3133", "volume": "23", "author": "S Kato", "year": "2017", "unstructured": "Kato, S.  et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin. Cancer Res. 23, 4242\u20134250 (2017).", "journal-title": "Clin. Cancer Res."}, {"key": "BFnrurol2017190_CR109", "doi-asserted-by": "publisher", "first-page": "46", "DOI": "10.1001/jamaoncol.2015.3638", "volume": "2", "author": "J McLaughlin", "year": "2016", "unstructured": "McLaughlin, J.  et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2, 46\u201354 (2016).", "journal-title": "JAMA Oncol."}, {"key": "BFnrurol2017190_CR110", "doi-asserted-by": "publisher", "first-page": "1158", "DOI": "10.1158/2326-6066.CIR-15-0043", "volume": "3", "author": "M Callea", "year": "2015", "unstructured": "Callea, M.  et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res. 3, 1158\u20131164 (2015).", "journal-title": "Cancer Immunol. Res."}, {"key": "BFnrurol2017190_CR111", "doi-asserted-by": "publisher", "first-page": "34", "DOI": "10.1186/s13073-017-0424-2", "volume": "9", "author": "ZR Chalmers", "year": "2017", "unstructured": "Chalmers, Z. R.  et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).", "journal-title": "Genome Med."}, {"key": "BFnrurol2017190_CR112", "doi-asserted-by": "publisher", "first-page": "152", "DOI": "10.1016/j.ccr.2014.01.009", "volume": "25", "author": "W Choi", "year": "2014", "unstructured": "Choi, W.  et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152\u2013165 (2014).", "journal-title": "Cancer Cell"}, {"key": "BFnrurol2017190_CR113", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.lungcan.2016.05.025", "volume": "107", "author": "I Bahce", "year": "2017", "unstructured": "Bahce, I.  et al. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET. Lung Cancer 107, 1\u201313 (2017).", "journal-title": "Lung Cancer"}, {"key": "BFnrurol2017190_CR114", "doi-asserted-by": "publisher", "first-page": "e1329071", "DOI": "10.1080/2162402X.2017.1329071", "volume": "6", "author": "M Kikuchi", "year": "2017", "unstructured": "Kikuchi, M.  et al. Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. Oncoimmunology 6, e1329071 (2017).", "journal-title": "Oncoimmunology"}, {"key": "BFnrurol2017190_CR115", "doi-asserted-by": "publisher", "first-page": "855", "DOI": "10.1016/j.eururo.2015.08.034", "volume": "69", "author": "DJ McConkey", "year": "2016", "unstructured": "McConkey, D. J.  et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 69, 855\u2013862 (2016).", "journal-title": "Eur. Urol."}], "container-title": ["Nature Reviews Urology"], "language": "en", "link": [{"URL": "http://www.nature.com/articles/nrurol.2017.190.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/articles/nrurol.2017.190", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://www.nature.com/doifinder/10.1038/nrurol.2017.190", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}, {"URL": "http://www.nature.com/articles/nrurol.2017.190.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 10, 2]], "date-time": "2019-10-02T02:04:57Z", "timestamp": 1569981897000}, "score": 41.441772, "issued": {"date-parts": [[2017, 12, 5]]}, "references-count": 115, "journal-issue": {"published-print": {"date-parts": [[2018, 2]]}, "issue": "2"}, "alternative-id": ["BFnrurol2017190"], "URL": "http://dx.doi.org/10.1038/nrurol.2017.190", "relation": {"cites": []}, "ISSN": ["1759-4812", "1759-4820"], "issn-type": [{"value": "1759-4812", "type": "print"}, {"value": "1759-4820", "type": "electronic"}], "assertion": [{"value": "5 December 2017", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "A.S.-R. declares associations with AstraZeneca, Bristol-Myers Squibb (BMS), Eisai, EMD Serono, Genentech, Janssen, Merck, Threshold Pharmaceuticals, Inovio, and Vertex as a member of the scientific advisory boards and has acted as a speaker and preceptor for Genentech. B.C. declares receipt of honoraria from Prometheus Pharmaceuticals; research funding from BMS, MedImmune, and Prometheus Pharmaceuticals; and funding for travel expenses from BMS, MedImmune, and Prometheus Pharmaceuticals.", "order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Competing interests"}}]}, {"indexed": {"date-parts": [[2019, 11, 24]], "date-time": "2019-11-24T03:50:37Z", "timestamp": 1574567437098}, "reference-count": 10, "publisher": "Elsevier BV", "issue": "1", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2015, 1, 1]], "date-time": "2015-01-01T00:00:00Z", "timestamp": 1420070400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Lancet Oncology"], "published-print": {"date-parts": [[2015, 1]]}, "DOI": "10.1016/s1470-2045(14)71187-8", "type": "journal-article", "created": {"date-parts": [[2014, 12, 11]], "date-time": "2014-12-11T09:03:20Z", "timestamp": 1418288600000}, "page": "9-10", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Towards effective adjuvant treatment for urothelial cancer"], "prefix": "10.1016", "volume": "16", "author": [{"given": "Arlene O", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}, {"given": "Jianjun", "family": "Gao", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["The Lancet Oncology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1470204514711878?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1470204514711878?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 8, 18]], "date-time": "2019-08-18T10:01:27Z", "timestamp": 1566122487000}, "score": 41.34391, "issued": {"date-parts": [[2015, 1]]}, "references-count": 10, "journal-issue": {"published-print": {"date-parts": [[2015, 1]]}, "issue": "1"}, "alternative-id": ["S1470204514711878"], "URL": "http://dx.doi.org/10.1016/s1470-2045(14)71187-8", "ISSN": ["1470-2045"], "issn-type": [{"value": "1470-2045", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T23:53:50Z", "timestamp": 1576799630878}, "reference-count": 14, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "8", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JCO"], "published-print": {"date-parts": [[2017, 3, 10]]}, "DOI": "10.1200/jco.2016.71.6134", "type": "journal-article", "created": {"date-parts": [[2017, 2, 23]], "date-time": "2017-02-23T17:11:27Z", "timestamp": 1487869887000}, "page": "816-817", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer"], "prefix": "10.1200", "volume": "35", "author": [{"given": "Arlene O.", "family": "Siefker-Radtke", "sequence": "first", "affiliation": [{"name": "Arlene O. Siefker-Radtke and Matthew T. Campbell, The University of Texas MD Anderson Cancer Center, Houston, TX"}]}, {"given": "Matthew T.", "family": "Campbell", "sequence": "additional", "affiliation": [{"name": "Arlene O. Siefker-Radtke and Matthew T. Campbell, The University of Texas MD Anderson Cancer Center, Houston, TX"}]}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "language": "en", "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.71.6134", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T20:32:22Z", "timestamp": 1574886742000}, "score": 40.719467, "issued": {"date-parts": [[2017, 3, 10]]}, "references-count": 14, "journal-issue": {"published-print": {"date-parts": [[2017, 3, 10]]}, "issue": "8"}, "alternative-id": ["10.1200/JCO.2016.71.6134"], "URL": "http://dx.doi.org/10.1200/jco.2016.71.6134", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T15:20:18Z", "timestamp": 1574522418796}, "publisher-location": "New York, NY", "reference-count": 24, "publisher": "Springer New York", "isbn-type": [{"value": "9781461453192", "type": "print"}, {"value": "9781461453208", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012]]}, "DOI": "10.1007/978-1-4614-5320-8_9", "type": "book-chapter", "created": {"date-parts": [[2012, 12, 14]], "date-time": "2012-12-14T20:20:12Z", "timestamp": 1355516412000}, "page": "173-181", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Small Cell Urothelial Carcinoma"], "prefix": "10.1007", "author": [{"given": "Anil", "family": "Parwani", "sequence": "first", "affiliation": []}, {"given": "Colin", "family": "Dinney", "sequence": "additional", "affiliation": []}, {"given": "Arlene", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 11, 6]]}, "reference": [{"key": "9_CR00091", "author": "CN Sternberg", "first-page": "322", "year": "1997", "unstructured": "Sternberg CN, Swanson DA. Non-transitional cell bladder cancer. In: Raghavan D, Scher HI, Leiber SA, Lange P, editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott - Raven Publishers; 1997. p. 322\u20133.", "volume-title": "Principles and practice of genitourinary oncology"}, {"issue": "6", "key": "9_CR00092", "doi-asserted-by": "publisher", "first-page": "1172", "DOI": "10.1002/cncr.20903", "volume": "103", "author": "NW Choong", "year": "2005", "unstructured": "Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103(6):1172\u20138.", "journal-title": "Cancer"}, {"issue": "5", "key": "9_CR00093", "doi-asserted-by": "publisher", "first-page": "957", "DOI": "10.1002/cncr.20456", "volume": "101", "author": "L Cheng", "year": "2004", "unstructured": "Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004;101(5):957\u201362.", "journal-title": "Cancer"}, {"issue": "2", "key": "9_CR00094", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1097/01.ju.0000132413.85866.fc", "volume": "172", "author": "AO Siefker-Radtke", "year": "2004", "unstructured": "Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004;172(2):481\u20134.", "journal-title": "J Urol"}, {"issue": "16", "key": "9_CR00095", "doi-asserted-by": "publisher", "first-page": "2592", "DOI": "10.1200/JCO.2008.19.0256", "volume": "27", "author": "AO Siefker-Radtke", "year": "2009", "unstructured": "Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27(16):2592\u20137.", "journal-title": "J Clin Oncol"}, {"issue": "4", "key": "9_CR00096", "first-page": "285", "volume": "167", "author": "PJ Walther", "year": "2002", "unstructured": "Walther PJ. Adjuvant/neo-adjuvant etoposide/cisplatin and cystectomy for management of invasive small cell carcinoma of the bladder. J Urol. 2002;167(4):285.", "journal-title": "J Urol"}, {"issue": "1", "key": "9_CR00097", "doi-asserted-by": "publisher", "first-page": "93", "DOI": "10.1097/01.ju.0000162085.20043.1f", "volume": "174", "author": "ML Quek", "year": "2005", "unstructured": "Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, et al. Radical cystectomy for \u00adprimary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol. 2005;174(1):93\u20136.", "journal-title": "J Urol"}, {"issue": "1", "key": "9_CR00098", "doi-asserted-by": "publisher", "first-page": "57", "DOI": "10.1111/j.1365-2559.2004.01980.x", "volume": "46", "author": "NA Abrahams", "year": "2005", "unstructured": "Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005;46(1):57\u201363.", "journal-title": "Histopathology"}, {"issue": "6", "key": "9_CR00099", "doi-asserted-by": "publisher", "first-page": "1347", "DOI": "10.1002/1097-0142(19890915)64:6<1347::AID-CNCR2820640629>3.0.CO;2-Q", "volume": "64", "author": "CE Blomjous", "year": "1989", "unstructured": "Blomjous CE, Vos W, De Voogt HJ, Van der Valk P, Meijer CJ. Department of Pathology FUHATN. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer. 1989;64(6):1347\u201357.", "journal-title": "Cancer"}, {"issue": "1", "key": "9_CR000910", "doi-asserted-by": "publisher", "first-page": "12", "DOI": "10.1111/j.1464-410X.2003.04893.x", "volume": "94", "author": "P Sved", "year": "2004", "unstructured": "Sved P, Gomez P, Manoharan M, Civantos F, Soloway MS. Small cell carcinoma of the bladder. BJU Int. 2004;94(1):12\u20137.", "journal-title": "BJU Int"}, {"issue": "2", "key": "9_CR000911", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.1002/1097-0142(19920115)69:2<527::AID-CNCR2820690241>3.0.CO;2-7", "volume": "69", "author": "DJ Grignon", "year": "1992", "unstructured": "Grignon DJ, Ro JY, Ayala AG, Shum DT, Ord\u00e2o\u00e4nez NG, Logothetis CJ, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer. 1992;69(2):527\u201336.", "journal-title": "Cancer"}, {"issue": "2", "key": "9_CR000912", "doi-asserted-by": "crossref", "first-page": "382", "DOI": "10.1016/S0022-5347(17)37800-X", "volume": "146", "author": "ME Christopher", "year": "1991", "unstructured": "Christopher ME, Seftel AD, Sorenson K, Resnick MI. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J Urol. 1991;146(2):382\u20138.", "journal-title": "J Urol"}, {"issue": "5", "key": "9_CR000913", "doi-asserted-by": "publisher", "first-page": "1533", "DOI": "10.1016/S0002-9440(10)62369-3", "volume": "166", "author": "L Cheng", "year": "2005", "unstructured": "Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166(5):1533\u20139.", "journal-title": "Am J Pathol"}, {"issue": "5", "key": "9_CR000914", "first-page": "791", "volume": "133", "author": "EF Tamas", "year": "2009", "unstructured": "Tamas EF, Stephenson AJ, Campbell SC, Montague DK, Trusty DC, Hansel DE. Histopathologic features and clinical outcomes in 71 cases of bladder diverticula. Arch Pathol Lab Med. 2009;133(5):791\u20136.", "journal-title": "Arch Pathol Lab Med"}, {"issue": "Suppl 2", "key": "9_CR000915", "doi-asserted-by": "publisher", "first-page": "S96", "DOI": "10.1038/modpathol.2009.26", "volume": "22", "author": "MB Amin", "year": "2009", "unstructured": "Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22 Suppl 2:S96\u2013118.", "journal-title": "Mod Pathol"}, {"issue": "2", "key": "9_CR000916", "first-page": "217", "volume": "25", "author": "M Pant-Purohit", "year": "2010", "unstructured": "Pant-Purohit M, Lopez-Beltran A, Montironi R, MacLennan GT, Cheng L. Small cell carcinoma of the urinary bladder. Histol Histopathol. 2010;25(2):217\u201321.", "journal-title": "Histol Histopathol"}, {"issue": "6", "key": "9_CR000917", "first-page": "E30", "volume": "96", "author": "N Ismaili", "year": "2009", "unstructured": "Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay JY, Droz JP, et al. Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer. 2009;96(6):E30\u201344.", "journal-title": "Bull Cancer"}, {"issue": "2", "key": "9_CR000918", "doi-asserted-by": "publisher", "first-page": "94", "DOI": "10.1177/1066896909359914", "volume": "18", "author": "N Buza", "year": "2010", "unstructured": "Buza N, Cohen PJ, Pei H, Parkash V. Inverse p16 and p63 expression in small cell carcinoma and high-grade urothelial cell carcinoma of the urinary bladder. Int J Surg Pathol. 2010;18(2):94\u2013102.", "journal-title": "Int J Surg Pathol"}, {"issue": "5", "key": "9_CR000919", "doi-asserted-by": "publisher", "first-page": "617", "DOI": "10.1016/S0090-4295(99)80290-8", "volume": "46", "author": "F Abbas", "year": "1995", "unstructured": "Abbas F, Civantos F, Benedetto P. Small cell carcinoma of the bladder and prostate. Urology. 1995;46(5):617\u201330.", "journal-title": "Urology"}, {"issue": "4", "key": "9_CR000920", "doi-asserted-by": "publisher", "first-page": "323", "DOI": "10.1159/000019870", "volume": "35", "author": "R Bast\u00e2us", "year": "1999", "unstructured": "Bast\u00e2us R, Caballero JM, Gonz\u00e2alez G, Borrat P, Casalots J, Gomez de Segura G. Small cell carcinoma of the urinary bladder treated with chemotherapy and radiotherapy: results in five cases. Eur Urol. 1999;35(4):323\u20136.", "journal-title": "Eur Urol"}, {"issue": "1", "key": "9_CR000921", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.1007/s00345-008-0304-x", "volume": "27", "author": "A Bex", "year": "2009", "unstructured": "Bex A, de Vries R, Pos F, Kerst M, Horenblas S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol. 2009;27(1):101\u20136.", "journal-title": "World J Urol"}, {"issue": "4", "key": "9_CR000922", "doi-asserted-by": "publisher", "first-page": "711", "DOI": "10.1111/j.1464-410X.2006.06041.x", "volume": "97", "author": "TR Asmis", "year": "2006", "unstructured": "Asmis TR, Reaume MN, Dahrouge S, Malone S. Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at the Ottawa Hospital Regional Cancer Center. BJU Int. 2006;97(4):711\u20135.", "journal-title": "BJU Int"}, {"issue": "11", "key": "9_CR000923", "doi-asserted-by": "publisher", "first-page": "2346", "DOI": "10.1002/(SICI)1097-0142(19991201)86:11<2346::AID-CNCR24>3.0.CO;2-5", "volume": "86", "author": "C Lohrisch", "year": "1999", "unstructured": "Lohrisch C, Murray N, Pickles T, Sullivan L, British Columbia Cancer Agency VBCC. Small cell \u00adcarcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999;86(11):2346\u201352.", "journal-title": "Cancer"}, {"issue": "14", "key": "9_CR000924", "doi-asserted-by": "publisher", "first-page": "3072", "DOI": "10.1200/JCO.2002.12.065", "volume": "20", "author": "CN Papandreou", "year": "2002", "unstructured": "Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20(14):3072\u201380.", "journal-title": "J Clin Oncol"}], "container-title": ["The Urinary Tract"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4614-5320-8_9", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 10]], "date-time": "2019-05-10T00:21:00Z", "timestamp": 1557447660000}, "score": 39.274704, "issued": {"date-parts": [[2012]]}, "ISBN": ["9781461453192", "9781461453208"], "references-count": 24, "URL": "http://dx.doi.org/10.1007/978-1-4614-5320-8_9", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T13:57:52Z", "timestamp": 1574517472324}, "publisher-location": "New York, NY", "reference-count": 19, "publisher": "Springer New York", "isbn-type": [{"value": "9781461451969", "type": "print"}, {"value": "9781461451976", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2013]]}, "DOI": "10.1007/978-1-4614-5197-6_14", "type": "book-chapter", "created": {"date-parts": [[2012, 11, 22]], "date-time": "2012-11-22T18:11:54Z", "timestamp": 1353607914000}, "page": "143-152", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Bladder Cancer"], "prefix": "10.1007", "author": [{"given": "Robert S.", "family": "Svatek", "sequence": "first", "affiliation": []}, {"given": "Ashish M.", "family": "Kamat", "sequence": "additional", "affiliation": []}, {"given": "Arlene", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}, {"given": "Colin P. N.", "family": "Dinney", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2012, 10, 26]]}, "reference": [{"key": "14_CR00141", "doi-asserted-by": "publisher", "first-page": "225", "DOI": "10.3322/caac.20006", "volume": "59", "author": "A Jemal", "year": "2009", "unstructured": "Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225\u201349.", "journal-title": "CA Cancer J Clin"}, {"key": "14_CR00142", "doi-asserted-by": "publisher", "first-page": "10", "DOI": "10.3322/canjclin.55.1.10", "volume": "55", "author": "A Jemal", "year": "2005", "unstructured": "Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10\u201330.", "journal-title": "CA Cancer J Clin"}, {"key": "14_CR00143", "author": "E Messing", "year": "2007", "edition": "9", "unstructured": "Messing E. Campbell-Walsh urology. 9th ed. St. Louis: W.B. Saunders; 2007.", "volume-title": "Campbell-Walsh urology"}, {"key": "14_CR00144", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1016/j.urolonc.2007.07.010", "volume": "27", "author": "PC Black", "year": "2009", "unstructured": "Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009;27:3\u20137.", "journal-title": "Urol Oncol"}, {"key": "14_CR00145", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.1007/s11934-008-0011-6", "volume": "9", "author": "PC Black", "year": "2008", "unstructured": "Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep. 2008;9:55\u201361.", "journal-title": "Curr Urol Rep"}, {"key": "14_CR00146", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1016/j.ucl.2005.02.004", "volume": "32", "author": "L Adam", "year": "2005", "unstructured": "Adam L, Kassouf W, Dinney CP. Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am. 2005;32:239\u201346. vii.", "journal-title": "Urol Clin North Am"}, {"key": "14_CR00147", "doi-asserted-by": "publisher", "first-page": "807", "DOI": "10.1586/era.09.32", "volume": "9", "author": "RS Svatek", "year": "2009", "unstructured": "Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009;9:807\u201313.", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "14_CR00148", "doi-asserted-by": "publisher", "first-page": "62", "DOI": "10.1002/cncr.22756", "volume": "110", "author": "AM Kamat", "year": "2007", "unstructured": "Kamat AM, Dinney CP, Gee JR, et al. Micropapillary bladder cancer: a review of the University of Texas MD. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007;110:62\u20137.", "journal-title": "Cancer"}, {"key": "14_CR00149", "doi-asserted-by": "publisher", "first-page": "881", "DOI": "10.1016/S0022-5347(05)00423-4", "volume": "175", "author": "AM Kamat", "year": "2006", "unstructured": "Kamat AM, Gee JR, Dinney CP, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175:881\u20135.", "journal-title": "J Urol"}, {"key": "14_CR001410", "doi-asserted-by": "publisher", "first-page": "481", "DOI": "10.1097/01.ju.0000132413.85866.fc", "volume": "172", "author": "AO Siefker-Radtke", "year": "2004", "unstructured": "Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M.D. Anderson cancer experience. J Urol. 2004;172:481\u20134.", "journal-title": "J Urol"}, {"key": "14_CR001411", "doi-asserted-by": "publisher", "first-page": "2592", "DOI": "10.1200/JCO.2008.19.0256", "volume": "27", "author": "AO Siefker-Radtke", "year": "2009", "unstructured": "Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27:2592\u20137.", "journal-title": "J Clin Oncol"}, {"key": "14_CR001412", "doi-asserted-by": "crossref", "first-page": "269s", "DOI": "10.1200/jco.2008.26.15_suppl.5079", "volume": "26", "author": "A Siefker-Radtke", "year": "2008", "unstructured": "Siefker-Radtke A, Millikan RE, Kamat AM, et al. A phase II trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine (IAG), followed by cisplatin, gemcitabine, and ifosfamide (CGI) in locally advanced urothelial cancer: Final results from the MD Anderson Cancer Center. J Clin Oncol. 2008;26:269s.", "journal-title": "J Clin Oncol"}, {"key": "14_CR001413", "doi-asserted-by": "publisher", "first-page": "57", "DOI": "10.1111/j.1365-2559.2004.01980.x", "volume": "46", "author": "NA Abrahams", "year": "2005", "unstructured": "Abrahams NA, Moran C, Reyes AO, et al. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005;46:57\u201363.", "journal-title": "Histopathology"}, {"key": "14_CR001414", "doi-asserted-by": "publisher", "first-page": "2113", "DOI": "10.1097/01.ju.0000067601.29966.4a", "volume": "169", "author": "P Sweeney", "year": "2003", "unstructured": "Sweeney P, Millikan R, Donat M, et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 2003;169:2113\u20137.", "journal-title": "J Urol"}, {"key": "14_CR001415", "doi-asserted-by": "publisher", "first-page": "877", "DOI": "10.1586/14737140.6.6.877", "volume": "6", "author": "A Siefker-Radtke", "year": "2006", "unstructured": "Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther. 2006;6:877\u201385.", "journal-title": "Expert Rev Anticancer Ther"}, {"key": "14_CR001416", "doi-asserted-by": "publisher", "first-page": "859", "DOI": "10.1056/NEJMoa022148", "volume": "349", "author": "HB Grossman", "year": "2003", "unstructured": "Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366.", "journal-title": "N Engl J Med"}, {"key": "14_CR001417", "doi-asserted-by": "crossref", "first-page": "4005", "DOI": "10.1200/JCO.2001.19.20.4005", "volume": "19", "author": "R Millikan", "year": "2001", "unstructured": "Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001;19:4005\u201313.", "journal-title": "J Clin Oncol"}, {"key": "14_CR001418", "doi-asserted-by": "crossref", "first-page": "3068", "DOI": "10.1200/JCO.2000.18.17.3068", "volume": "18", "author": "H Maase von der", "year": "2000", "unstructured": "von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377.", "journal-title": "J Clin Oncol"}, {"key": "14_CR001419", "doi-asserted-by": "crossref", "first-page": "2638", "DOI": "10.1200/JCO.2001.19.10.2638", "volume": "19", "author": "CN Sternberg", "year": "2001", "unstructured": "Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638\u201346.", "journal-title": "J Clin Oncol"}], "container-title": ["60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4614-5197-6_14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 9]], "date-time": "2019-05-09T01:33:12Z", "timestamp": 1557365592000}, "score": 38.074005, "issued": {"date-parts": [[2012, 10, 26]]}, "ISBN": ["9781461451969", "9781461451976"], "references-count": 19, "URL": "http://dx.doi.org/10.1007/978-1-4614-5197-6_14", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 12, 19]], "date-time": "2019-12-19T21:20:47Z", "timestamp": 1576790447008}, "reference-count": 0, "publisher": "American Society of Clinical Oncology (ASCO)", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2002, 3, 1]]}, "DOI": "10.1200/jco.20.5.1361", "type": "journal-article", "created": {"date-parts": [[2002, 7, 27]], "date-time": "2002-07-27T13:13:48Z", "timestamp": 1027775628000}, "page": "1361-1367", "source": "Crossref", "is-referenced-by-count": 44, "title": ["Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer"], "prefix": "10.1200", "volume": "20", "author": [{"given": "A. O.", "family": "Siefker-Radtke", "sequence": "first", "affiliation": []}], "member": "233", "container-title": ["Journal of Clinical Oncology"], "link": [{"URL": "http://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.5.1361", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T20:45:04Z", "timestamp": 1574887504000}, "score": 36.8778, "issued": {"date-parts": [[2002, 3, 1]]}, "references-count": 0, "journal-issue": {"issue": "5"}, "URL": "http://dx.doi.org/10.1200/jco.20.5.1361", "ISSN": ["0732-183X", "1527-7755"], "issn-type": [{"value": "0732-183X", "type": "print"}, {"value": "1527-7755", "type": "electronic"}], "subject": ["Cancer Research", "Oncology"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T09:35:21Z", "timestamp": 1574415321193}, "reference-count": 3, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2010, 4, 1]], "date-time": "2010-04-01T00:00:00Z", "timestamp": 1270080000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["European Urology"], "published-print": {"date-parts": [[2010, 4]]}, "DOI": "10.1016/j.eururo.2010.01.029", "type": "journal-article", "created": {"date-parts": [[2010, 3, 2]], "date-time": "2010-03-02T09:50:06Z", "timestamp": 1267523406000}, "page": "728-729", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Re: Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium"], "prefix": "10.1016", "volume": "57", "author": [{"given": "Christopher J.", "family": "Logothetis", "sequence": "first", "affiliation": []}, {"given": "Arlene", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["European Urology"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0302283810000643?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0302283810000643?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 12]], "date-time": "2018-12-12T22:52:48Z", "timestamp": 1544655168000}, "score": 36.66776, "issued": {"date-parts": [[2010, 4]]}, "references-count": 3, "journal-issue": {"published-print": {"date-parts": [[2010, 4]]}, "issue": "4"}, "alternative-id": ["S0302283810000643"], "URL": "http://dx.doi.org/10.1016/j.eururo.2010.01.029", "ISSN": ["0302-2838"], "issn-type": [{"value": "0302-2838", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:22:48Z", "timestamp": 1574108568849}, "reference-count": 17, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 11, 1]], "date-time": "2003-11-01T00:00:00Z", "timestamp": 1067644800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Urologic Oncology: Seminars and Original Investigations"], "published-print": {"date-parts": [[2003, 11]]}, "DOI": "10.1016/s1078-1439(03)00148-0", "type": "journal-article", "created": {"date-parts": [[2003, 12, 18]], "date-time": "2003-12-18T10:35:35Z", "timestamp": 1071743735000}, "page": "464-467", "source": "Crossref", "is-referenced-by-count": 7, "title": ["Neoadjuvant chemotherapy for bladder cancer"], "prefix": "10.1016", "volume": "21", "author": [{"given": "Randall", "family": "Millikan", "sequence": "first", "affiliation": []}, {"given": "Arlene", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}, {"given": "H.Barton", "family": "Grossman", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Urologic Oncology: Seminars and Original Investigations"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1078143903001480?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1078143903001480?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 16]], "date-time": "2019-02-16T03:51:25Z", "timestamp": 1550289085000}, "score": 36.333313, "issued": {"date-parts": [[2003, 11]]}, "references-count": 17, "journal-issue": {"published-print": {"date-parts": [[2003, 11]]}, "issue": "6"}, "alternative-id": ["S1078143903001480"], "URL": "http://dx.doi.org/10.1016/s1078-1439(03)00148-0", "ISSN": ["1078-1439"], "issn-type": [{"value": "1078-1439", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T01:38:21Z", "timestamp": 1574473101397}, "reference-count": 91, "publisher": "Elsevier", "isbn-type": [{"value": "9781437722321", "type": "print"}], "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 1, 1]], "date-time": "2012-01-01T00:00:00Z", "timestamp": 1325376000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012]]}, "DOI": "10.1016/b978-1-4377-2232-1.00019-x", "type": "book-chapter", "created": {"date-parts": [[2012, 4, 30]], "date-time": "2012-04-30T19:34:04Z", "timestamp": 1335814444000}, "page": "311-333", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Bladder Cancer and Upper Tracts"], "prefix": "10.1016", "author": [{"given": "Chaan S.", "family": "Ng", "sequence": "first", "affiliation": []}, {"given": "Arlene O.", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}, {"given": "Ashish", "family": "Kamat", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Oncologic Imaging: A Multidisciplinary Approach"], "link": [{"URL": "https://api.elsevier.com/content/article/PII:B978143772232100019X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:B978143772232100019X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 6, 28]], "date-time": "2019-06-28T03:30:44Z", "timestamp": 1561692644000}, "score": 35.994343, "issued": {"date-parts": [[2012]]}, "ISBN": ["9781437722321"], "references-count": 91, "URL": "http://dx.doi.org/10.1016/b978-1-4377-2232-1.00019-x"}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T00:38:09Z", "timestamp": 1574296689108}, "reference-count": 9, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3165, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer"], "published-print": {"date-parts": [[2007, 7, 1]]}, "DOI": "10.1002/cncr.22756", "type": "journal-article", "created": {"date-parts": [[2007, 5, 31]], "date-time": "2007-05-31T23:16:26Z", "timestamp": 1180653386000}, "page": "62-67", "source": "Crossref", "is-referenced-by-count": 168, "title": ["Micropapillary bladder cancer"], "prefix": "10.1002", "volume": "110", "author": [{"given": "Ashish M.", "family": "Kamat", "sequence": "first", "affiliation": []}, {"given": "Colin P. N.", "family": "Dinney", "sequence": "additional", "affiliation": []}, {"given": "Jason R.", "family": "Gee", "sequence": "additional", "affiliation": []}, {"given": "H. Barton", "family": "Grossman", "sequence": "additional", "affiliation": []}, {"given": "Arlene O.", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": []}, {"given": "Pheroze", "family": "Tamboli", "sequence": "additional", "affiliation": []}, {"given": "Michelle A.", "family": "Detry", "sequence": "additional", "affiliation": []}, {"given": "Tracy L.", "family": "Robinson", "sequence": "additional", "affiliation": []}, {"given": "Louis L.", "family": "Pisters", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2007]]}, "reference": [{"key": "10.1002/cncr.22756-BIB1", "author": "Jemal", "volume": "56", "first-page": "106", "year": "2006", "journal-title": "CA Cancer J Clin.", "DOI": "10.3322/canjclin.56.2.106", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB2", "author": "Amin", "volume": "18", "first-page": "1224", "year": "1994", "journal-title": "Am J Surg Pathol.", "DOI": "10.1097/00000478-199412000-00005", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB3", "author": "Johansson", "volume": "161", "first-page": "1798", "year": "1999", "journal-title": "J Urol.", "DOI": "10.1016/S0022-5347(05)68807-6", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB4", "author": "Kamat", "volume": "175", "first-page": "881", "year": "2006", "journal-title": "J Urol.", "DOI": "10.1016/S0022-5347(05)00423-4", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB5", "author": "Millikan", "volume": "19", "first-page": "4005", "year": "2001", "journal-title": "J Clin Oncol.", "DOI": "10.1200/JCO.2001.19.20.4005", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB6", "author": "Samaratunga", "volume": "45", "first-page": "55", "year": "2004", "journal-title": "Histopathology.", "DOI": "10.1111/j.1365-2559.2004.01895.x", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB7", "author": "Bristow", "volume": "95", "first-page": "791", "year": "2002", "journal-title": "Cancer.", "DOI": "10.1002/cncr.10789", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB8", "author": "Siefker-Radtke", "volume": "172", "first-page": "481", "year": "2004", "journal-title": "J Urol.", "DOI": "10.1097/01.ju.0000132413.85866.fc", "doi-asserted-by": "crossref"}, {"key": "10.1002/cncr.22756-BIB9", "author": "Ruggeri", "volume": "106", "first-page": "783", "year": "2006", "journal-title": "Cancer.", "DOI": "10.1002/cncr.21676", "doi-asserted-by": "crossref"}], "container-title": ["Cancer"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.22756", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.22756", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 1, 31]], "date-time": "2019-01-31T00:41:54Z", "timestamp": 1548895314000}, "score": 35.688427, "subtitle": ["A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients"], "issued": {"date-parts": [[2007]]}, "references-count": 9, "journal-issue": {"published-print": {"date-parts": [[2007, 7, 1]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1002/cncr.22756", "relation": {"cites": []}, "ISSN": ["0008-543X", "1097-0142"], "issn-type": [{"value": "0008-543X", "type": "print"}, {"value": "1097-0142", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T05:10:50Z", "timestamp": 1574831450450}, "reference-count": 19, "publisher": "Future Medicine Ltd", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Immunotherapy"], "published-print": {"date-parts": [[2017, 9]]}, "DOI": "10.2217/imt-2017-0073", "type": "journal-article", "created": {"date-parts": [[2017, 9, 7]], "date-time": "2017-09-07T13:34:00Z", "timestamp": 1504791240000}, "page": "781-784", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer"], "prefix": "10.2217", "volume": "9", "author": [{"given": "Amishi Y", "family": "Shah", "sequence": "first", "affiliation": [{"name": "Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe, Unit 1374, Houston, TX 77030, USA"}]}, {"given": "Jianjun", "family": "Gao", "sequence": "additional", "affiliation": [{"name": "Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe, Unit 1374, Houston, TX 77030, USA"}]}, {"given": "Arlene O", "family": "Siefker-Radtke", "sequence": "additional", "affiliation": [{"name": "Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe, Unit 1374, Houston, TX 77030, USA"}]}], "member": "1057", "reference": [{"key": "B1", "DOI": "10.1126/science.aaa8172", "doi-asserted-by": "publisher"}, {"key": "B2", "DOI": "10.1016/S0022-5347(17)58737-6", "doi-asserted-by": "publisher"}, {"key": "B3", "DOI": "10.1111/j.1442-2042.2007.01696.x", "doi-asserted-by": "publisher"}, {"key": "B4", "DOI": "10.1016/j.urolonc.2005.11.026", "doi-asserted-by": "publisher"}, {"key": "B5", "DOI": "10.1016/j.juro.2010.06.147", "doi-asserted-by": "publisher"}, {"key": "B6", "DOI": "10.1200/JCO.2002.20.5.1361", "doi-asserted-by": "publisher"}, {"key": "B7", "DOI": "10.1016/j.juro.2013.03.030", "doi-asserted-by": "publisher"}, {"key": "B8", "DOI": "10.1158/1078-0432.CCR-10-0569", "doi-asserted-by": "publisher"}, {"key": "B9", "DOI": "10.1016/S0140-6736(16)00561-4", "doi-asserted-by": "publisher"}, {"key": "B10", "DOI": "10.1016/S1470-2045(17)30065-7", "doi-asserted-by": "publisher"}, {"key": "B11", "DOI": "10.1200/JCO.2016.67.9761", "doi-asserted-by": "publisher"}, {"key": "B12", "DOI": "10.1200/JCO.2016.71.6795", "doi-asserted-by": "publisher"}, {"key": "B14", "DOI": "10.1016/S0140-6736(16)32455-2", "doi-asserted-by": "publisher"}, {"key": "B15", "author": "O'donnel P", "year": "2017", "volume-title": "2017 ASCO Annual Meeting"}, {"key": "B16", "DOI": "10.1056/NEJMoa1613683", "doi-asserted-by": "publisher"}, {"issue": "20090", "key": "B17", "first-page": "1", "volume": "6", "author": "Sheng J", "year": "2016", "journal-title": "Sci. Rep."}, {"key": "B18", "author": "Mcconkey D", "volume": "69", "first-page": "855", "year": "2016", "journal-title": "Eur. Eurol.", "DOI": "10.1016/j.eururo.2015.08.034", "doi-asserted-by": "crossref"}, {"key": "B19", "DOI": "10.1016/j.hoc.2014.11.003", "doi-asserted-by": "publisher"}, {"key": "B20", "DOI": "10.1038/ncomms14979", "doi-asserted-by": "publisher"}], "container-title": ["Immunotherapy"], "language": "en", "link": [{"URL": "https://www.futuremedicine.com/doi/pdf/10.2217/imt-2017-0073", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T09:56:16Z", "timestamp": 1574243776000}, "score": 35.3699, "issued": {"date-parts": [[2017, 9]]}, "references-count": 19, "journal-issue": {"published-print": {"date-parts": [[2017, 9]]}, "issue": "10"}, "alternative-id": ["10.2217/imt-2017-0073"], "URL": "http://dx.doi.org/10.2217/imt-2017-0073", "relation": {"cites": []}, "ISSN": ["1750-743X", "1750-7448"], "issn-type": [{"value": "1750-743X", "type": "print"}, {"value": "1750-7448", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}